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ABSTRACT 
 
One of the major hallmarks of Parkinson’s disease (PD) is the deposition 
of intracellular Lewy body inclusions. α-Synuclein is a small protein that 
accumulates and aggregates to form Lewy bodies. Recent studies uncovered 
variation of α-synuclein mRNA 3’ untranslated region (UTR), but the role of this 
region in regulating the α-synuclein expression is poorly understood. 3’UTR is a 
target region for RNA binding proteins and microRNAs (miRs) in regulating 
protein translation from the mRNA transcript. Leucine-rich repeat kinase 2 
(LRRK2) is a key regulator of miR-mediated translational repression and is 
frequently mutated and causally associated with PD. We hypothesize that 
	  	   xviii 
LRRK2 regulates α-synuclein expression post-transcriptionally via binding of miR 
to α-synuclein mRNA’s 3’UTR. 
We have found that α-synuclein mRNA with short 3’UTR has similar 
protein expression level to that of long 3’UTR in the absence of LRRK2 in both 
HEK-293 FT cells and primary hippocampal neurons. However, LRRK2 wild-type 
and disease mutant G2019S increased α-synuclein protein expression. In 
particular, an increase of 2-fold was observed for the short 3’UTR transcript, 
which is significantly greater than the increase for the long isoform. These data 
suggest differential effects of LRRK2 on α-synuclein depending on the length of 
3’UTR.  
The short 3’UTR of the α-synuclein transcript has a binding site for miR-7; 
whereas, that of the long isoform has binding sites for miR-7 and miR-153. We 
discovered that these differential effects of LRRK2 on α-synuclein are dependent 
on the binding of miR-7 and miR-153 to the 3’UTR of the isoforms. Specifically, 
miR-7 is a stronger mediator in regulating α-synuclein translation compared to 
miR-153, leading to an approximately 30% inhibition of α-synuclein protein 
expression.  
Our studies have also shown that the effects of LRRK2 on regulating α-
synuclein protein expression are dependent on LRRK2 kinase activity. Gain-of-
kinase-function mutation, G2019S, leads to a greater increase of α-synuclein 
protein expression compared to wild-type; whereas, inhibition of LRRK2 kinase 
function decreases its effect on α-synuclein protein expression. These findings 
	  	   xix 
highlight novel mechanisms regulating the expression of α-synuclein involving 
LRRK2, miRs-7 and -153. These results highlight miRs as potential targets for 
reducing levels of α-synuclein in PD.  
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PREFACE 
Most experiments outlined in this dissertation are organized in the format 
of manuscripts in preparation or submitted. 
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Parkinson’s Disease 
 
Epidemiology 
Parkinson’s Disease (PD) is the most common age-related motor disorder 
affecting nearly 1 million Americans (Ferree, et al., 2012; Hsu, et al., 2010; Nutt & 
Wooten, 2005). With the loss of over 60% of dopaminergic neurons in the 
nigrostriatal system, patients with PD exhibit various signs of motor deficiencies 
(Ferree, et al., 2012). These symptoms include bradykinesia, resting tremor, 
rigidity, gait disorder, and postural instability (Ferree, et al., 2012; Savitt, Dawson, 
& Dawson, 2006). However, the molecular mechanisms leading to the 
susceptibility of this sub-population of dopaminergic neurons to 
neurodegeneration in PD remain unknown. The prevalence and incidence of PD 
increase as the population ages. Over 1% of the elderly population over the age 
of 65 develops PD, where more men than women are afflicted. There is no 
difference in prevalence across race and ethnicity (Nutt & Wooten, 2005). 
 
Diagnosis 
Patients are diagnosed with PD if they presented with the four motor 
symptoms of PD, which are bradykinesia, resting tremor, postural instability and 
rigidity (Nutt & Wooten, 2005). In 75% of PD patients, bradykinesia starts 
unilaterally  (Gelb, Oliver, & Gilman, 1999). Resting tremor is also often a 
unilateral symptom (Nut & Wooten, 2005). Early PD patients may also 
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experience tremor, imbalance, stiffness, and slowness, despite their neurological 
exam being normal (de Lau, Koudstaal, Hofman, & Breteler, 2006). Accurate 
diagnosis is commonly hindered by the heterogeneity and complexity of PD, 
which leads to approximately 10-25% of misdiagnosis (Hughes, Daniel, Ben-
Shlomo, & Lees, 2002; Rajput, Rozdilsky, & Rajput, 1991; Suchowersky, Reich, 
Perlmutter, Zesiewicz, Gronseth, & Weiner, 2006; Tolosa, Wenning, & Poewe, 
2006). 
 
Parkinsonism 
 Parkinsonism is a broad term that describes a group of diseases 
characterized by PD cardinal symptoms. PD accounts for approximately 75% of 
parkinsonism. Other diseases that may also present with parkinsonism include 
essential tremor, dementia with Lewy bodies, spinocerebellar ataxia, corticobasal 
degeneration, progressive supranuclear palsy, frontotemporal dementia with 
parkinsonism linked to chromosome 17, Huntington’s disease, multiple system 
atrophy  (Tolosa, Wenning, & Poewe, 2006). Infection, metabolic diseases, 
toxins, drugs, and neoplasm, may also lead to parkinsonism (Ahkskog, 2000; 
Farrer, 2006; Tolosa, Wenning, & Poewe, 2006). 
 
Idiopathic and familial PD  
 Idiopathic PD may result from a combination of factors, which includes 
age, genetic predisposition, environmental toxins, and neuroinflammation (Fahn 
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& Sulzer, 2004; West, et al., 2007) and is typically referred as the clinically 
typical, late-onset, and non-inheritable parkinsonism that is responsive to 
dopaminergic therapy. However, PD patients with certain familial monogenic 
mutations may present clinically and pathologically indistinguishable from 
idiopathic PD patients (Albanese, Valente, Romito, Bellacchio, Elia, & 
Dallapiccola, 2005; Klein, et al., 2000; Lohmann, et al., 2003; Wszolek, et al., 
2004). Within familial forms of PD and some sporadic idiopathic diseases, 
mutations in Leucine-Rich Repeat Kinase 2 (LRRK2) are the most common 
genetic cause of PD, where at least 20 mutations in LRRK2 have been identified 
to date that cause autosomal-dominant PD, accounting for approximately 7% of 
all familial cases (Farrer, et al., 2005; Mata, et al., 2006). The most prevalent 
mutation is the amino acid substitution of G2019S, which is located in the kinase 
domain of LRRK2 and can lead to PD that is clinically indistinguishable from 
idiopathic disease (Mata, et al., 2006).  
 
Current pharmacological treatments 
 Currently, the main pharmacological treatment of PD is derived from the 
discovery of the loss of dopaminergic neurons in the substantia nigra pars 
compacta leading to dopaminergic deficiency in the striatum (Sourkes & Poirier, 
1965). These treatments aim at increasing dopamine (DA) levels in patients’ 
brains to replace the loss of dopaminergic neurons in the substantia nigra pars 
compacta and they replace dopaminergic deficiency by DA replacement, 
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activation of DA synthesis, and DA receptors agonists or increasing DA release. 
Among all, the most common treatment to increase the level of DA in the brain is 
levodopa, which is a precursor of DA (Cotzias, 1968; Cotzias, Papavasiliou, & 
Gellene, Experimental treatment of parkinsonism with L-Dopa, 1968). More 
recent treatments aim to decrease peripheral side-effects; such as vomiting and 
nausea, caused by levodopa metabolism outside of the brain. Carbidopa, a 
peripheral decarboxylase inhibitor (or benserazide), inhibits the metabolism of 
levodopa in the periphery and thus eliminates the side-effects of vomiting and 
nausea and can enhance the entrance level of levipdopa into the brain (Rinne, 
Sonninen, & Siirtola, 1972; Rinne & Sonninen, 1973; Rinne & Mölsä, 1979). 
Catechol-O-methyltransferase (COMT) inhibitors can increase the half-life of 
levodopa and dopamine, which in turn enhance the efficacy of the treatment 
(Ericsson, 1971; Roberts, Cora-Locatelli, Bravi, Amantea, Mouradian, & Chase, 
1993; Myllylä, Sotaniemi, Illi, Suominen, & Keränen, 1993). Monoamine oxidase 
type B (MAO-B) inhibitors; such as, selegiline can also increase the half-life of 
endogenous DA (Chrisp, Mammen, & Sorkin, 1991; Olanow, 1993; Nutt, 1998). 
In the 2000s, DA agonists; such as, ropinerole and pramiprexole, are effective in 
certain patients. They are not effective in patients who do not respond to 
levodopa treatment and they remain less effective than levodopa for those who 
respond to levodopa (Rascol, Brooks, Korczyn, De Deyn, Clarke, & Lang, 2000; 
Lees, Katzenschlager, Head, & Ben-Shlomo, 2001; Holloway, et al., 2004). 
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Current surgical interventions 
For patients who do not respond to pharmacological treatments or have 
severe adverse effects associated with levodopa therapy, which include 
intolerable motor fluctuations and hallucinations resulting from levodopa 
treatment over time, surgical interventions are recommended, such as, deep 
brain stimulation (DBS) (Benabid, et al., 2009; Umemura, Oka, Okita, 
Matsukawa, & Yamada, 2011). However, none of these treatments work for all 
PD patients and some have considerable complications and severe adverse 
effects. Degeneration of dopaminergic neurons in substantial nigra pars 
compacta causes excessive subthalamic nucleus (STN) excitation, which in turn 
causing an increase in internal globus pallidus (GPi) excitation, leading to 
inhibition of the thalamus. Decreased thalamocortical activity causes akinesia 
and rigidity symptoms. For DBS, an electrode is inserted through the skull and a 
pacemaker-like device is implanted to control the stimulation of the GPi, STN, or 
ventral intermediate thalamus. The targeted suppression of the GPi reduces the 
excessive inhibitory effect of the pallidus on thalamocortical activity. This 
treatment can be quite effective. It is also completely reversible and does not 
destroy the brain tissue (Savitt, Dawson, & Dawson, 2006). 
 
Non-motor symptoms and their treatments 
 Besides motor symptoms, PD patients suffer from many non-motor 
symptoms as well, including sleep disturbance, depression, fatigue, constipation, 
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anxiety, cognitive impairment. (de Lau, Koudstaal, Hofman, & Breteler, 2006). 
Several pharmacological agents have been used to relieve these symptoms. For 
example, serotonin selective reuptake inhibitors (SSRIs) are commonly used to 
treated depression (Miyasaki, et al., 2006). In addition, cholinesterase 
antagonists can be used to treat cognitive decline. These non-motor and 
autonomic symptoms of PD indicate that PD is not dopaminergic-specific, but 
rather a complex disease that encompasses the degeneration of multiple 
neuronal cell types in different brain regions and systems.  
 
Summary 
 In summary, a combination of pharmacological and surgical treatments 
may provide symptomatic relief to the motor and non-motor symptoms of PD. 
However, most of these treatments lose their efficacy over time. Also, some 
treatments lead to undesirable side-effects as well. Currently, there are no 
treatments for PD that can halt the disease progression nor can they restore the 
neuronal loss in affected brain regions. Hopefully, a better understanding of the 
underlying molecular mechanisms leading to PD will provide insights for potential 
novel therapies for PD patients that can stop disease progression or even restore 
functional loss due to neuronal loss.  
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Pathogenesis of PD 
 
Neuropathology 
The pathology of PD includes depigmentation, neuronal loss and gliosis in 
the substantia nigra pars compacta  (Pakkenberg, Møller , Gundersen , 
Mouritzen Dam, & Pakkenberg, 1991). The first clinical symptom occurs when 
there is a loss of over 60% of neurons in the substantia nigra pars compacta  
(Shen, 2004; Hornykiewicz, 2006). One of the neuropathological hallmarks of PD 
is Lewy bodies (LBs). LBs are intracellular proteinaceous inclusions containing α-
synuclein, ubiquitin and other proteins (Wakabayashi, Hansen, & Masliah, 1995; 
Trojanowski & Lee, 1998; Dickson, 1999; Wakabayashi & Takahashi, 2000). 
Majority of PD patients have LBs in their substantia nigra, basal nucleus of 
Meynert, locus coeruleus, cortex, and other areas in the brain and 10% of normal 
aging elders’ brains also contain LBs (Popescu, Lippa, Lee, & Trojanowski, 
2004). However, the role of LB deposition in the pathogenesis of PD is unknown. 
Some have speculated that LBs being large intracellular aggregates of proteins 
may inhibit normal neuronal function (Trojanowski, Goedert, Iwatsubo, & Lee, 
1998), whereas, others have suggested LBs may be neuroprotective by 
sequestering malfunctioning proteins in order to allow normal neuronal 
functioning (Wakabayashi & Takahashi, 2000).  
In a comprehensive neuropathological study, Braak et al.(2002) 
characterized 41 clinically-diagnosed PD brains, 69 non-PD diagnosed brains 
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with thread-like Lewy neurites (LNs) and/or LBs, and 58 age- and gender-
matched controls for the localization of α-synucleinpositive LNs and LBs. Braak 
et al. (2002) categorized the pathologic process of PD into six stages, which 
begins with pathological changes in the medulla and the olfactory bulb, and 
progresses rostrally through six distinct stages over decades, demonstrating PD 
is not a dopaminergic-specific disorder and the vulnerabilities of non-
dopaminergic neurons in PD can be responsible for other non-motor symptoms 
of PD such as cognitive decline, anxiety and depression (Braak, Del Tredici, 
Bratzke, Hamm-Clement, Sandmann-Keil, & Rüb , 2002; Braak, Rüb, & Del 
Tredici, 2006; Savitt, Dawson, & Dawson, 2006; Dickson, Uchikado, Fujishiro, & 
Tsuboi, 2010).  
 
Environmental factors 
No environmental factor has been proven to cause PD. However, many 
toxins have been associated with parkinsonism. Chronic exposure to 
mitochondrial complex I inhibitor; such as, 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) and rotenone have been shown to cause 
parkinsonism and selective degeneration of the substantia nigral dopaminergic 
neurons (Betarbet, Sherer, MacKenzie, Garcia-Osuna, Panov, & Greenamyre, 
2000). MPTP is a heroin contaminant and can lead to acute parkinsonism by 
attacking dopaminergic neurons specifically, as its metabolite, MPP+, inhibits 
complex 1 in the mitochondria (Betarbet, Sherer, MacKenzie, Garcia-Osuna, 
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Panov, & Greenamyre, 2000).  
 
Genetics  
The majority of PD cases are idiopathic, but the identification of genes 
responsible for familial parkinsonism has helped us better understand PD (Table 
1).  
One of the major hallmarks of PD is the accumulation of intracellular 
protein aggregates in LBs. Through studying the composition of LB, SNCA 
(PARK1), which encodes for α-synuclein, was one of the first genetic mutations 
linked to familial PD revealed  (Polymeropoulos, et al., 1997); where amino acid 
substitutions, A53T and A30P, were hypothesized to stimulate the aberrant 
aggregation of α-synuclein. To date, 13 other PARK loci have been found to be 
linked to familial PD and the better known ones are listed in Table 1.  
 Autosomal dominant mutations that lead to familial PD are found in α-
synuclein, LRRK2, and Ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) 
(Cookson & Bandmann, 2010). Mutations in these genes are hypothesized to 
have gain-of-function leading to monogenic PD. The ubiquitin-proteasomal 
system (UPS) and the mitochondrial oxidative stress pathways are two specific 
cellular pathways that have been shown to have an important role in the 
pathogenesis of PD (Vila & Przedborski, 2004). 
 Autosomal recessive mutations that lead to PD are found in Parkin, PINK1 
and DJ-1 (Kitada, et al., 1998; Bonifati, et al., 2003). The clinical symptoms in 
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autosomal recessive PD patients are quite different from idiopathic PD patients; 
for example, mutations in Parkin that lead to PD have rare LB (Pramstaller, et al., 
2005; Cookson & Bandmann, 2010). Parkin is an E3-ubiquitin ligase that is linked 
to the degradation of dysfunctional mitochondria in mitophagy (Lee, Nagano, 
Taylor, Kim, & Yao, 2010). DJ-1 is an oxidative stress signaling molecule but its 
exact function remains unknown (Cookson & Bandmann, 2010); whereas, PINK1 
is a mitochondrial serine/threonine kinase which recruit Parkin to dysfunctional 
mitochondria (Matsuda, et al., 2010).  
 
Locus Gene Phenotype  Common 
Mutations 
Disease 
Onset 
Protein Function 
PARK1 α-synuclein AD A53T, A30P, 
E46K 
Early Synaptic transmission 
PARK2 Parkin AR T240R Early E3 ubiquitin ligase  
PARK5 UCH-L1 AD I93M Early Ubiquitin carboxy-terminal 
hydrolase 
PARK6 PINK1 AR L347P  Early  Mitochondrial kinase  
PARK7 DJ-1 AR L166P, 
M261I, 
D149A, 
A104T, 
E64D 
Early Oxidative stress signaling 
molecule 
PARK8 LRRK2 AD G2019S, 
R1441C, 
Mostly 
Late 
Kinase and GTPase 
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I2020T  
PARK9 ATP13A2 Kufor-Rake 
Syndrome 
T12M, 
A1144T 
 Intracellular cation 
homeostasis. Maintenance 
of neuronal integrity 
PARK13 HTRA2 AD A141S, 
G339S  
 Activate Apoptosis  
PARK17 VPS35 
 
AD  D620N Adult-
onset 
Retrograde transport of 
proteins from endosomes to 
the trans-Golgi network 
GAD Glutamate 
decarboxylase 
 Deletion  Catalyzes decarboxylation 
of glutamate to GABA and 
CO2 
GBA Glucocerebro-
sidase 
Gaucher's 
disease 
L444P Late Synthesize enzyme beta-
glucocerebrosidase, which 
is active in lysosomes 
Table 1: Monogenic causes of PD. AD: autosomal dominant; AR: autosomal 
recessive; LB: Lewy bodies (Adapted from Savitt, Dawson, & Dawson, 2006). 
 
α-Synuclein 
α-synuclein protein was initially found to be aggregates in Lewy neurites 
and Lewy bodies, which is one of the neuropathological hallmarks of PD (Alim, et 
al., 2002; Popescu, Lippa, Lee, & Trojanowski, 2004; Ferree, et al., 2012), 
leading to the hypothesis that abnormal protein aggregation may lead to neuronal 
death in PD (Trojanowski, Goedert, Iwatsubo, & Lee, 1998). α-Synuclein is a 
major component of LBs and becomes hyperphosphorylated and ubiquitinated 
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aggregates and insoluble filaments (Spillantini, Crowther, Jakes, Hasegawa, & 
Goedert, 1998; Hasegawa, et al., 2002).  
α-synuclein (SNCA) was the first parkinsonism-associated gene that was 
discovered through studying LBs. It is a small protein, containing 140 amino 
acids with the N-terminus forming an amphipathic, α-helical domain when the 
protein associates with lipids (Cole & Murphy, 2002; Figure 1, adapted from 
Venda, Cragg, Buchman, & Wade-Martins, 2010). Mutations in the α-synuclein 
gene can lead to autosomal dominant PD, where patients display early disease 
onset with atypical symptoms such as myoclonus and more severe autonomic 
dysfunctions (Polymeropoulos, et al., 1997; Spira, Sharpe, Halliday, Cavanagh, & 
Nicholson, 2001; Lin, Tsai, Wu, & Chien, 2010). Three missense point mutations 
in the α-synuclein gene have been identified as A53T, A30P and E64K 
(Polymeropoulos, et al., 1997; Krüger, et al., 1998; Li, Uversky, & Fink, 2001; 
Zarranz, et al., 2004; Figure 1, adapted from Venda, Cragg, Buchman, & Wade-
Martins, 2010). The missense mutations alter the equilibrium between the lipid-
associated and free α-synuclein, which reduce the affinity of α-synuclein to lipid 
and therefore increasing the level of hyperphosphorylated cytoplasmic α-
synuclein and its propensity to form β-sheets and toxic oligomers (Lashuel, et al., 
2002). 
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Figure 1. Schematic representation of human α-synuclein (a) gene structure, (b) 
mRNA and (c) protein domains. The locations of putative pathogenic amino acid 
substitutions are highlighted in green in α-synuclein protein (Adapted from 
Venda, Cragg, Buchman, & Wade-Martins, 2010). 
 
 
Current studies have shown that increased SNCA gene dosage may lead 
to earlier disease onset and severity in wild-type α-synuclein mouse models and 
this was in concordance with the identification of families with duplicates or 
triplicates of the wild-type α-synuclein gene (Singleton, et al., 2003; Nishioka, et 
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al., 2006). In addition, studies have shown that mutant α-synuclein can inhibit 
chaperone-mediated autophagy (CMA), which can block its own degradation and 
other substrates (Cuervo, Stefanis, Fredenburg, Lansbury, & Sulzer, 2004).  
Recent studies have suggested that specific RNA transcript isoforms of α-
synuclein with an extended 3’ untranslated region (UTR) are selectively linked to 
Parkinson’s pathology (McLean, Hallett, Cooper, Stanley, & Isacson, 2012). 
Studies have also suggested that α-synuclein with long 3’UTR relative to α-
synuclein with short 3’UTR are more toxic. Abeliovich’s group from Columbia 
University has shown that the presence of the extended 3’UTR of α-synuclein 
transcript promoted the accumulation and translation of α-synuclein (Rhinn, et al., 
2012; Figure 2; adapted from Rhinn, et al., 2012). In summary, α-synuclein 
accumulations and aggregations are associated with PD pathology.   
 
 
 
 
 
Figure 2. Schematic representation of α-synuclein transcript isoform with short 3’ 
UTR (0.3 kb) and with long 3’ UTR (1.1 kb) (Adapted from Rhinn, et al., 2012).  
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Leucine-Rich Repeat Kinase 2 (LRRK2) 
 
Disease association 
The PARK8 locus (LRRK2 gene) was first mapped to chromosome 12p in 
a single Japanese family affected with PD and was later corroborated in many 
families around the world (Funayama, Hasegawa, Kowa, Saito, Tsuji, & Obata, 
2002). Mutations in leucine-rich repeat kinase 2 (LRRK2), are the most common 
genetic cause of PD, with at least 20 mutations identified to date causing late 
onset, familial autosomal-dominant PD, with same disease risk in populations 
with heterozygous or homozygous LRRK2 mutations (Hsu, et al., 2010; Ferree, 
et al., 2012; Orenstein, et al., 2013; Saha, Liu-Yesucevitz, & Wolozin, 2014) 
(Lesage, et al., 2006; Healy, et al., 2008; Ishihara, et al., 2006).  
Mutations in LRRK2 recapitulate symptoms indistinguishable from that of 
idiopathic PD. PD patients with LRRK2 mutations develop late onset PD, 
between 50-70 years old, with neuropathology consisting largely LBs, with the 
exception of a few consisting instead of nuclear inclusions and neurofibrillary 
tangles, and are responsive to dopaminergic therapies (Zimprich, et al., 2004). 
Two of the mutations that clearly segregate with PD are located in the 
kinase domain of LRRK2, G2019S and I2020T (Zimprich, et al., 2004; West, et 
al., 2005; Greggio, et al., 2006; West, et al., 2007). The most prevalent amino 
acid substitution in LRRK2 in Caucasian populations is G2019S. The G2019S 
mutation in LRRK2 accounts for 41% of familial PD in the North African Arab 
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population, 30% in the Ashkenazi Jewish population and 6% in Europe (Lesage, 
et al., 2006; Di Fonzo, et al., 2005; Gilks, et al., 2005; Kachergus, et al., 2005; 
Nichols, et al., 2005). Although G2019S mutation leads to autosomal dominant 
PD, the penetrance is incomplete. The risk of developing PD associated with 
G2019S mutation is 28% at the age of 59, 51% at the age of 69 and 74% at the 
age of 79 (Healy, et al., 2008; Gasser, 2009; Mata, et al., 2005; Lewis, Greggio, 
Beilina, Jain, Baker, & Cookson, 2007; Di Fonzo, et al., 2005). In addition, 
G2019S mutation has been found in 1-2% of sporadic PD cases and sporadic 
PD and LRRK2-associated PD are clinically and neurochemically 
indistinguishable (Healy, et al., 2008; Gasser, 2009; Mata, et al., 2005).  
 
Gene and protein structure 
The LRRK2 gene of 51 exons on chromosome 12q12 spans a genomic 
region of 144Kb and encodes LRRK2 protein, which is a large ubiquitous 
cytoplasmic protein consisting of 2527 amino acids with multiple functional 
domains (Greggio & Cookson, 2009; Dusonchet, et al., 2014; Mata, et al., 2006). 
It consists of an ankyrin repeat and leucine-rich repeat regions (LRR), kinase, 
Ras-of-complex proteins (ROC) GTPase, C-terminal of ROC (COR), a kinase 
and WD40 domains (West, et al., 2007; Greggio & Cookson, 2009; Hsu, et al., 
2010). 
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Figure 3. Schematic representation of LRRK2 domain structure The locations of 
putative pathogenic amino acid substitutions are highlighted in magenta; amino 
acid substitutions segregating with disease are shown in green; whereas, the 
corresponding exon numbers are shown in black. ANK: ankyrin repeat region, 
LRR: leucine-rich repeat domain, Roc: Ras of complex (GTPase), COR: C-
terminal of Ras, Ex: Exon (Adapted from Mata, et al., 2006).   
 
 
The two catalytic domains are the kinase and ROC GTPase domains. The 
kinase domain has the highest sequence homology to mitogen-activated protein 
kinase kinase kinase (MKKK)/MLKs (mixed lineage kinases) and receptor-
interacting protein (RIP) kinase families (Greggio & Cookson, 2009; West, et al., 
2007). Recent studies have shown that LRRK2 is a G-protein activated by 
nucleotide-dependent dimerization (GAD) and homodimerization of LRRK2 
through its COR domains will activate autophosphorylation, which activates the 
kinase domains of this complex (Greggio & Cookson, 2009; Deng, Lewis, 
Greggio, Sluch, Beilina, & Cookson, 2008; Gasper, Meyer, Gotthardt, Sirajuddin, 
& Wittinghofer, 2009).  
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Subcellular distribution 
LRRK2 protein expression has been found to be generally ubiquitous in 
the brain (Biskup, et al., 2006; Greggio, et al., 2006; Higashi, et al., 2007; 
Melrose, et al., 2007). At subcellular level, LRRK2 is present diffusely in the 
cytoplasm and excluded from the nucleus (West, et al., 2005). It can be 
associated with vesicular and membranous structures, which include 
mitochondria, lysosomes, endosomes, and transport vesicles (Biskup, et al., 
2006). It has been hypothesized that activated LRRK2 will translocate from the 
cytoplasm to these vesicular and membranous structures, where it will act as a 
scaffold to coordinate cellular stress response mechanisms (Berger, Smith, & 
Lavoie, 2010; Hsu, et al., 2010). Studies have shown that in HEK-293 T cells, the 
G2019S mutation increased the nuclear fraction of LRRK2 (Biskup, et al., 2006). 
On the other hand, both G2019S and R1441C mutations decreased LRRK2 
localization to mitochondrial fractions (West, et al., 2005).  
 
Anatomical distribution 
 LRRK2 protein expression is ubiquitous in the brain (Biskup, et al., 2006; 
Greggio, et al., 2006; Higashi, et al., 2007; Melrose, et al., 2007). Transgenic 
BAC mice carrying human LRRK2 show that both WT and transgenic hLRRK2 
mice brains have LRRK2 ubiquitously distributed throughout most brain regions 
(Melrose, et al., 2007), which includes the subventricular zone, suggesting 
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LRRK2 may have a role in neurogenesis (Melrose, et al., 2007). Although LRRK 
protein expression is mostly ubiquitous throughout the brain, its mRNA 
expression is most abundant in dopamine-innervated areas (Galter, Westerlund, 
Carmine, Lindqvist, Sydow, & Olson, 2006; Simón-Sánchez, Herranz-Pérez, 
Olucha-Bordonau, & Pérez-Tur , 2006; Taymans, Van den Haute, & Baekelandt, 
2006; Higashi, et al., 2007; Melrose, et al., 2007). Outside of the brain, LRRK2 is 
abundant in lymphoblasts (Melrose, et al., 2007).  
 
Pathogenic mutations in LRRK2 
 Mutations in LRRK2 are the most common genetic cause of autosomal 
dominant PD. The pathogenic mutations can be found in various domains within 
this large protein (Mata, et al., 2005; Cookson & Bandmann, 2010). The most 
prevalent pathogenic mutations are found in the kinase, ROC, and COR 
domains.  
 The G2019S amino acid substitution is the most prevalent mutation in 
familial PD and is located in the activating segment of the kinase domain (Mata, 
et al., 2006). The activating segment of protein kinases is usually a hinge-like 
region between a smaller N-terminal lobe and a larger C-terminal lobe, forming a 
cleft where the protein substrate and Mg2+-ATP can bind. In addition to G2019S, 
I2020T is another prominent mutation found in this region and both G2019S and 
I2020T were found to have enhanced kinase activity compare to WT LRRK2 
(West, et al., 2005; Gloeckner, et al., 2006).  
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 (A)                              (B) 
           
 
Figure 4. Homology models of LRRK2 depicting common pathogenic mutations. 
Putative pathogenic mutations are highlighted in magenta. Amino acid 
substitutions segregating with disease are shown in green. (A) Kinase domain: 
G2019S and I2020T mutations in the activating segment between the smaller N-
terminal lobe and the larger C-terminal lobe. (B) ROC GTPase domain: 
R1441C/G/J mutations (Adapted from Mata, et al., 2006).   
 
 
The other common amino acid substitutions are R1441C/G/H in the Roc 
GTPase domain and Y1699C in the COR domain (Zimprich, et al., 2004; Mata, et 
al., 2006; West, et al., 2007; Lewis, Greggio, Beilina, Jain, Baker, & Cookson, 
2007; Xiong, et al., 2010). The Roc GTPase domain of LRRK2 belongs to the 
Roco family, which is always found in tandem with the COR domain (Bosgraaf & 
Van Hasstert, 2003). The COR domain allows homodimerization, which 
augments GTP binding and leads to the activation of the enzyme (Gasper, 
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Meyer, Gotthardt, Sirajuddin, & Wittinghofer, 2009).  
The pathological mutation G2019S leads to a gain-of-function with an 
enhanced kinase activity without affecting the GTPase activity of LRRK2 (West, 
et al., 2005; Gloeckner, et al., 2006; whereas, R1441C/G/H and Y1699C, affect 
GTPase activity of LRRK2 by impairing GTP hydrolysis and have inconsistent 
effects on its kinase activity (Greggio, et al., 2006; Ito, et al., 2007; Li, Tan, 
Poulose, Olanow, Huang, & Yue, 2007; West, et al., 2007; Lewis, Greggio, 
Beilina, Jain, Baker, & Cookson, 2007; Daniëls , et al., 2011). These studies all 
indicate that LRRK2 has an important role in the pathogenesis of PD. However, 
the underlying mechanisms linking such mutations to pathology still remain 
unclear.  
 
LRRK2 in model organisms 
 Several model organisms have been created to study LRRK2 mutations in 
cellular functions. Caenorhabditis elegans (C.elegans), fruit fly Drosophila 
melanogaster, and rodent models have been utilized. C. elegans and Drosophila 
have shorter lifespans than rodents and are ideal for high-throughput drug 
screening. The mouse model is the preferred model for the study of 
neurodegeneration. However, mouse models with human mutations in LRRK2 do 
not show LB pathology and most mouse models do not have phenotypic 
differences that reflect parkinsonism symptoms as in human.  
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Interaction of LRRK2 with kinase and GTPase signaling cascades 
 
Adapted from Boon JY, Dusonchet J, Trengrove C., Wolozin B. Interaction of 
LRRK2 with kinase and GTPase signaling cascades. Front. Mol. Neurosci. 2014 
Jul 9;7:64. 
 
Abstract 
LRRK2 is a protein that interacts with a plethora of signaling molecules, 
but the complexity of LRRK2 functions presents a challenge for understanding 
the role of LRRK2 in the pathophysiology of Parkinson’s disease.  Studies of 
LRRK2 using over-expression in transgenic mice have been disappointing, 
however studies using invertebrate systems have yielded a much clearer picture, 
with clear effects of LRRK2 expression, knockdown or deletion in C. elegans and 
Drosophila on modulation of survival of dopaminergic neurons.  Recent studies 
have begun to focus attention on particular signaling cascades that are a target 
of LRRK2 function.  LRRK2 interacts with members of the MAPK pathway and 
might regulate the pathway action by acting as a scaffold that directs the location 
of MAPK pathway activity, without strongly affecting the amount of MAPK 
pathway activity.  Binding to GTPases, GAPs and GEFs are another strong 
theme in LRRK2 biology, with LRRK2 binding to Rac1, cdc42, rab5, rab7L1, 
endoA, RGS2, ArfGAP1 and ArhGEF7.  All of these molecules appear to feed 
into a function output for LRRK2 that modulates cytoskeletal outgrowth and 
	  	  
24 
vesicular dynamics, including autophagy.  These functions likely impact 
modulation of α-synuclein aggregation and associated toxicity eliciting the 
disease processes that we term Parkinson’s disease.  
 
Introduction 
Parkinson’s Disease (PD) is the most common age-related motor disorder 
(Ferree, et al., Regulation of physiologic actions of LRRK2: focus on autophagy, 
2012; Hsu, et al., 2010). Accumulation of aggregated α-synuclein to form Lewy 
bodies is a neuropathological hallmark for PD (Less, Hardy, & Revesz, 2009). 
Mutations in leucine-rich repeat kinase 2, LRRK2, gene are common genetic 
determinants of PD, with at least 20 different mutations identified to date causing 
late-onset, familial autosomal-dominant PD (Greene, 2012; Gasser, Hardy, & 
Mizuno, Milestones in PD genetics, 2011). The most prevalent amino acid 
substitution mutation in LRRK2, G2019S, has been found in 1-2% of sporadic PD 
cases; with sporadic PD and LRRK2-associated PD being clinically and 
neurochemically indistinguishable (Healy, et al., 2008). These all indicate that 
LRRK2 has an important role in the pathogenesis of PD.  
LRRK2 is a large ubiquitous cytoplasmic protein consisting of 2527 amino 
acids with multiple functional domains (Cookson, The role of leucine-rich repeat 
kinase 2 (LRRK2) in Parkinson's disease, 2010). LRRK2 has a homolog in 
mammals, termed LRRK1; LRRK1 and 2 expression appear to be 
complementary, with LRRK2 expression peaking in development and decreases 
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rapidly after birth, while LRRK2 expression increases postnatally (Simón-
Sánchez , Herranz-Pérez, Olucha-Bordonau, & Pérez-Tur , 2006). The LRRK2 
protein consists of kinase, Ras-of-complex proteins (ROC) GTPase, C-terminal 
of ROC (COR), leucine-rich repeat, ankyrin and WD40 domains (Cookson, The 
role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease, 2010). The 
two catalytic domains are the kinase and ROC GTPase domains. The kinase 
domain has the highest sequence homology to mitogen-activated protein kinase 
kinase kinase (MKKK)/MLKs (mixed lineage kinases) and receptor-interacting 
protein (RIP) kinase families. The most common mutation in LRRK2 associated 
with PD is the G2019S mutation located in the kinase domain of LRRK2 
(Wszolek, et al., 2004; Zimprich, et al., 2004). Other common amino acid 
substitution include R1441C/G/H in the Roc GTPase domain and Y1699C in the 
COR domain (Taylor, Mata, & Farrer, 2006). The pathological mutations G2019S 
enhances the kinase activity without affecting the GTPase activity of LRRK2; 
whereas R1441C/G/H and Y1699C affect GTPase activity of LRRK2 by impairing 
GTP hydrolysis and has inconsistent effects on its kinase activity  (West, et al., 
2005; Greggio, et al., 2006; Lewis, Greggio, Beilina, Jain, Baker, & Cookson, 
2007; Ito, et al., 2007; Li, Tan, Poulose, Olanow, Huang, & Yue, 2007). However, 
the underlying mechanisms linking such mutations to pathology still remain 
unclear.  
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LRRK2 Modulates Survival of Dopaminergic Neurons, Autophagy and Neuronal 
Outgrowth 
Studies of LRRK2 using over-expression in transgenic mice have been 
disappointing with few studies showing consistent effects occurring upon over-
expression of wild-type or mutant LRRK2 (Dawson, Ko, & Dawson, 2010). 
Knockout of LRRK2 in the mouse yielded a strong phenotype in the kidney 
pointing to a role for LRRK2 in autophagy, however no clear differences in the 
brain; this suggests that mammalian LRRK2 in vivo models do a better job of 
modeling cellular function/dysfunction rather than providing a more general 
model of Parkinson’s disease (Tong, et al., 2010). In contrast, over-expression 
studies using invertebrate systems have yielded much clearer results. Orthologs 
of LRRK2 also exist in Drosophila and nematodes, although these species 
exhibit just one form of LRRK, referred to as lrk-1 (Marin, 2008). The invertebrate 
LRRK2 orthologs have kinase, COR and ROC domains that are homologous to 
mammalian LRRK2, and the lrk-1 protein appears to subsume the functions of 
both LRRK1 and LRRK2 (Marin, 2008; Saha, et al., 2009). Studies from several 
groups examining the effects of LRRK2 expression, knockdown or deletion in C. 
elegans and Drosophila all show strong effects (Saha, et al., 2009; Yao, et al., 
2010; Sämann , Hegermann , von Gromoff , Eimer, Baumeister, & Schmidt, 
2009; Liu, et al., 2008; Venderova, et al., 2009; Wang, et al., 2008; Yuan, et al., 
2011). The results appear to differ somewhat based on the system, but the 
effects are strong in all cases.  Studies in our laboratory indicate that expressing 
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WT LRRK2 promotes survival of dopaminergic neurons in response rotenone 
treatment, while mutant LRRK2 (G2019S or R1441C) enhances loss of 
dopaminergic neurons relative to WT (Saha, et al., 2009). Another important 
aspect of our observations, which becomes important when considering studies 
of LRRK2 more generally, is that G2019S also potentiates loss of neuronal 
processes relative to WT LRRK2.  Because nematodes lack endogenous α-
synuclein, we recently crossed the LRRK2 lines to a line expressing α-synuclein 
in dopaminergic neurons.  Interestingly, current studies with a new nematode 
model in our laboratory shows that both WT and G2019S LRRK2 potentiate age 
related loss of dopaminergic neurons (and of their processes), suggesting that 
understanding the interaction between LRRK2 and α-synuclein is important for 
modeling the pathophysiology of PD. Studies from the Chen laboratory using a 
different C. elegans model (without incorporation of α-synuclein) show a 
deleterious effect of WT and G2019S LRRK2, while studies using drosophila 
indicate that LRRK2 potentiates degeneration of retinal cells and loss of 
dopaminergic neurons (Yao, et al., 2010; Liu, et al., 2008). Thus, the specific 
results depend on the particular model used, but it is clear that invertebrate 
models are very sensitive to modulation of LRRK2 levels, and mutations in 
LRRK2 potentiate degeneration of dopaminergic neurons.  While mouse models 
are not particularly sensitive to LRRK2 over-expression, knockout of LRRK2 
appears to potentiate autophagic deficits in the kidney, which is a site that 
normally exhibits strong expression of LRRK2.  This provides evidence that the 
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effects observed with invertebrate systems have strong relevance to the 
mammalian system. 
Studies using primary rodent neurons grown in culture have yielded much 
stronger results than the transgenic mouse models.  These studies consistently 
indicate that expression of mutant LRRK2 potentiates neurodegeneration, and 
reduces neurite outgrowth (Skibinski, Nakamura, Cookson, & Finkbeiner, 2014; 
Chan, Citro, Cordy, Shen, & Wolozin, 2011; Smith, et al., 2005). Interestingly, 
acute expression of WT LRRK2 appears to be beneficial, which parallels 
observations from our studies in C. elegans.  One study, using in utero 
electroporation of LRRK2 in the rodent brain also observed detrimental effects of 
G2019S LRRK2 and beneficial effects of WT LRRK2, suggesting that acute 
expression of LRRK2 in the rodent brain might produce clearer results than 
chronic over-expression, such as occurs with transgenic mice (MacLeod, 
Dowman, Hammond, Leete, Inoue, & Abeliovich, 2006). Taken together, these 
results indicate that mutant LRRK2 is detrimental; the effects of WT LRRK2 are 
less clear, with some data suggesting that WT LRRK2 is beneficial, and other 
data suggesting that over-expression can be mildly detrimental.  In general, most 
data suggest that loss of LRRK2 expression is detrimental. 
 
LRRK2 Regulates MAP Kinase Signaling Pathways 
Incorporating research from multiple different venues suggests roles for 
LRRK2 in two differing cellular networks.  Prior studies from our laboratory, and 
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subsequent studies from the Kahle laboratory indicate that LRRK2 interacts with 
the mitogen activated protein kinase (MAPK) pathways (Hsu, et al., 2010; Hsu, 
Chan, & Wolozin, 2010; Carballo-Carbajal, et al., 2010). The MAPK pathway is a 
signaling network that begins with membrane signaling and extends through 
multiple successive kinases leading ultimately to phosphorylation of transcription 
factors that act on gene expression (Yang, Sharrocks, & Whitmarsh, 2013). 
Receptor signaling frequently begins with MAP Kinase kinase kinases 
(MAPKKKs, also termed mixed lineage kinases, MLKs), which are enzymes often 
act to initiate signaling cascades that ultimately lead to transcriptional regulation 
(Yang, Sharrocks, & Whitmarsh, 2013). The MLK family of kinases activates the 
c-jun NH2-terminal kinase (JNK) pathway by phosphorylating MKK4 and -7 and 
activates the p38 pathway by phosphorylating MKK3 and -6 (Gallo & Johnson, 
2002; Wang, Besirli, & Johnson, 2004). These stress kinase complexes required 
scaffold proteins in the regulation of their subcellular localization. In particular for 
the MAP kinase signaling cascades, the JNK-interacting proteins (JIPs) are the 
group of scaffold proteins in such regulation (Kelkar, Standen, & Davis, 2005; 
Whitmarsh, 2006). Hence, these MKKs are then recruited into a multi-protein 
complex by scaffold proteins JIPs (Verhey, et al., 2001). JIP1-3 regulates the 
specificity and localization of the JNK pathway and JIP4 is a specific scaffolding 
protein for the p38 pathway (Kelkar, Standen, & Davis, 2005; Whitmarsh, 2006; 
Verhey, et al., 2001). 
Multiple studies show that LRRK2 interacts with the MAPK pathway and 
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has a kinase domain that is homologous to MAPKKK/MLKs and RIPs (Hsu, et 
al., 2010; West, et al., 2005; Hsu, Chan, & Wolozin, 2010; Carballo-Carbajal, et 
al., 2010; Greggio & Cookson, 2009). However, these same studies suggest that 
LRRK2 is not a strong activator of the pathway. Our laboratory has shown that 
LRRK2 binds MKK6, -3, and -7 in HEK-293 FT  (Hsu, et al., 2010; Gloeckner, 
Schumacher, Boldt, & Ueffing, 2009). Binding of LRRK2 to MKK6, -3, and -7, 
activates the p38 and c-jun NH2-terminal kinase (JNK) pathway, but the amount 
of activation is strikingly modest (Hsu, et al., 2010). Receptor activation of the 
MAPK pathway produces many fold increases in the activities of the downstream 
kinases, but over-expressing LRRK2 increases activities of the kinases and 
downstream transcription factors by 60% or less (Hsu, et al., 2010).  Studies from 
the Kahle laboratory showed similarly low levels of kinase activation upon LRRK2 
over-expression (Carballo-Carbajal, et al., 2010). These studies showed that 
LRRK2 upregulates alpha-synuclein transcription in parallel with MEK/ERK 
activation. This induction of transcriptional upregulation of alpha-synuclein was 
suppressed by treatment with the selective MAPK/ERK kinase inhibitor, U0126 
(Carballo-Carbajal, et al., 2010). Disease linked mutations increased activation 
by only an additional 25 – 30%. Similar results were observed upon analysis of 
JIP proteins, which act as scaffolds for MAPKs, and function in transport of 
MAPKs (Hsu, Chan, & Wolozin, 2010). We have also shown that LRRK2 binds to 
JIP1-4 and is associated with increased levels of total JIP1, -3, -4, oligomeric JIP 
and ubiquitinated JIP. In addition, G2019S, R1441C and I2020T (but not 
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Y1699C) mutations in LRRK2 increased binding with MKK6 and also levels of 
JIP4 (Hsu, Chan, & Wolozin, 2010). The stimulation of JIP oligomerization was 
particularly striking effect observed upon co-expression of LRRK2 with JIPs. 
Despite the relatively modest effect of LRRK2 on the MAPK cascades, 
LRRK2 produces a robust effect in vivo, and the MAPKs appear to be necessary 
for this function.  Our in vivo studies in C. elegans showed robust protection 
against mitochondrial stress that was induced by LRRK2 expression.  This 
protection was dependent on the action of MKK6 or p38 because RNAi 
knockdown of endogenous orthologs of MKK6 or P38 (sek-1 and pmk-1) or 
deletion of sek-1 in C. elegans abolish neuroprotection by LRRK2 (Hsu, et al., 
2010). The MAPK cascade also appears to modulate the effects of LRRK2 on 
autophagy (Plowey, Cherra, Liu, & Chu, 2008). Using redox proteomics, we also 
demonstrated that LRRK2 regulates proteins associated with the lysosome, 
including ATPVA6 (Di Domenico, et al., 2012). Application of a MAPKK (MEK) 
inhibitor blocked the effects of LRRK2 on autophagy and on neurite shortening 
(Plowey, Cherra, Liu, & Chu, 2008). Thus, interactions between LRRK2 and 
members of the MAPK pathway cause significant physiological effects despite 
causing only modest changes in phosphorylation.   
The discordance between the modest effects of LRRK2 on activation of 
the MAPK pathway and the strong effects of LRRK2 in protecting dopaminergic 
neurons in the nematode, or the strong effect of LRRK2 on JIP oligomerization 
demands a novel model to explain LRRK2 function.  One possibility is that 
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LRRK2 acts as a scaffold that directs the location of MAPK pathway activity, 
without strongly affecting the amount of MAPK pathway activity.  Location is as 
important to enzymatic action as amount of activity.  JIPs for instance, are 
thought to function in vesicular trafficking.  If LRRK2 also exhibited a role in 
vesicular trafficking, then it could impact on neuronal function by directing 
particular enzymes towards trafficked vesicles, rather than explicitly activating the 
MAPK pathway.  Such a role would also be consistent with other studies 
suggesting a function for LRRK2 in regulating small GTPases associated with 
vesicles. 
 
LRRK2 Regulates Many Other Signaling Cascades 
Recent transcriptome and proteome studies emphasize the diverse 
number of pathways regulated by LRRK2.  Studies by the Dawson group recently 
highlighted regulation of translational functions by LRRK2, showing that LRRK2 
binds to and phosphorylates the ribosomal protein RPS15 (Martin, et al., 2014). 
This observation fits well with other studies showing roles for LRRK2 as a 
negative mediator of miR mediated translational repression (Gehrke, Imai, Sokol, 
& Lu, 2010). The regulatory network that we developed also identifies RPS15 as 
a primary member of the LRRK2 regulatory network, interacting with LRRK2 in a 
pathway that includes the ADP-ribose polymerase TNKS (Dusonchet, et al., 
2014). The Cookson group also recently published a proteomic study of LRRK2, 
which identified Cyclin-G associated Kinase (GAK) as a strong binding protein 
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(Beilina, et al., 2014). GAK is the third strongest genetic risk factor for 
Parkinson’s disease, after synuclein and tau (Dumitriu, et al., 2011; Pankratz, et 
al., 2009). 
Other studies identify LRRK2 as a negative regulator of PKA signaling, 
acting through direct interaction with PKAR11B, modulating neuronal 
development and function, by influencing dopamine signaling and 
synaptogenesis  (Parisiadou, et al., 2014). The R1441C LRRK2 mutation exhibits 
similar neuronal effects on LRRK2 knockout mice, causing dopamine signaling 
impairments as well as neurite retraction via enhanced PKA activation. PKA also 
regulates LRRK2 by phosphorylating S1444 in the ROC domain; 14-3-3 then 
binds to the phospho-serine 1444 and inhibits LRRK2 kinase activity (Muda, et 
al., 2014). Binding of 14-3-3 to different phospho-epitopes (Ser-910/935) appears 
to stabilize LRRK2, while reduced binding destabilizes LRRK2 and causes 
aggregation of LRRK2 to form cytoplasmic inclusions (Dzamko, et al., 2010). 
Identification of targets of LRRK2 kinase activity remains unclear.  Studies have 
identified numerous putative substrates, including MAPK, 4E-BP and Tau 
(Berwick & Harvey, 2011; Imai, et al., 2008; Bailey, et al., 2013). 
Although LRRK2 has gained the most attention for its putative role in 
modulating dopamine function, LRRK2 also exerts regulation over immune 
responses. LRRK2 inhibits the transcription factor NFAT, which plays important 
roles in immune function as well as inflammatory bowel disease (Liu, Lee, 
Krummey, Lu, Cai, & Lenardo, 2011). Upon overexpression of LRRK2, NFAT 
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remains cytosolic, and is unable to translocate into the nucleus, which 
suppresses its transcriptional activity (Liu, Lee, Krummey, Lu, Cai, & Lenardo, 
2011). The MyD88 pathway is an additional pathway that is associated with the 
role of LRRK2 in immune function. Upon inflammation, TLR signaling via the 
MyD88 pathway leads to phosphorylation of LRRK2, implicating LRRK2 in 
macrophage biology (Dzamko, et al., 2012). 
 
LRRK2 Regulates Small GTPases 
A repeating theme in LRRK2 biology is its interactions with small 
GTPases.  The ROC domain in LRRK2 is striking because it forms homo- and 
hetero- dimers with LRRK2 and LRRK2, respectively, in vitro (Hsu, et al., 2010; 
Kumar, et al., 2010; Shin, et al., 2008). The tendency of the LRRK2 ROC domain 
to dimerize appears to belie a broader biological characteristic, which is an ability 
to bind multiple small GTPases.  As described below, we have shown that 
LRRK2 binds the small GTPase, rac1 (Chan, Citro, Cordy, Shen, & Wolozin, 
2011). This observation parallels other studies showing that LRRK2 binds to or is 
functionally dependent on other small GTPases, such as rab5, rab7L1 and 
endoA (Beilina, et al., 2014; Matta, et al., 2012). Additionally, LRRK2 binds 
multiple GTP modulating proteins (described in following sections).  In the case 
of rac1, the interactions of LRRK2 appears to regulate the site of action of the 
small GTPase, and leads to strong effects on the cytoskeleton, and for arfGEF7, 
they regulate the growth cone (Häbig, et al., 2013). 
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The interaction between LRRK2 and rac1 was observed by co-
immunoprecipitation.  LRRK2 could immunoprecipitate with rac1 upon 
overexpression in cell lines (HEK-293 FT cells), as well as from endogenous 
human brain striatum; in contrast binding to Cdc42 was weak and binding to 
RhoA was not apparent (Chan, Citro, Cordy, Shen, & Wolozin, 2011). Specificity 
of the interaction was shown by selective precipitation of rac1, without 
precipitation of the other classic Rho GTPases – Cdc42 and RhoA, although 
another study did find evidence for interaction of LRRK2 with cdc42 (Chan, Citro, 
Cordy, Shen, & Wolozin, 2011; Häbig, et al., 2013). The interaction between 
LRRK2 and rac1 occurs through the ROC-COR Kinase domains. Co-expressing 
LRRK2 and rac1 enhanced rac1 activity by increasing binding of rac1 to p21-
activated kinase, which in turn modulates actin cytoskeletal dynamics. LRRK2 
with inactivated kinase or GTPase domains does not activate rac1 (Chan, Citro, 
Cordy, Shen, & Wolozin, 2011). LRRK2 does not increase membrane-bound 
rac1, but it significantly changes the cellular localization of rac1, causing 
polarization, which is further augmented when LRRK2 is co-expressed with 
constitutively active rac1. G2019S and R1441C LRRK2 mutations decrease rac1 
binding; whereas Y1699C and I2020T increase rac1 binding.  
Rac1 is known to play an important role in actin cytoskeleton remodeling 
that is required for the maintenance of neurite morphology (Chan, Citro, Cordy, 
Shen, & Wolozin, 2011). The interaction between LRRK2 and rac1 results in 
distinct effects associated with changes in the actin cytoskeleton.  Previous 
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studies have shown that G2019S induces neurite retraction in both in vitro and in 
vivo studies through the MAPK signaling pathway and such pathology precedes 
dopaminergic neuronal death by apoptosis (Hsu, Chan, & Wolozin, 2010; 
Carballo-Carbajal, et al., 2010; Plowey, Cherra, Liu, & Chu, 2008; Parisiadou, et 
al., 2009; Liou, Leak, Li, & Zigmond, 2008; Hsu, et al., 2010). In SH-SY5Y cells, 
co-expression of rac1 and G2019S has shown to rescue neurite retraction 
induced by G2019S. These studies suggest that mutations in LRRK2 can lead to 
a decrease in activation of rac1, which causes disassembly of actin filaments 
leading to neurite retraction (Chan, Citro, Cordy, Shen, & Wolozin, 2011). 
 
Systems Biology Provides a Comprehensive Assessment of Cellular Pathways 
Interacting with LRRK2  
The studies showing LRRK2 interacting with many varied cellular proteins 
present a challenge for understanding its function. LRRK2 has been suggested 
to bind to  many different proteins, including moesin, tubulin, MKK3, 6 and 7, 
JIP1, 3, and 4, arfGAP1, arhGEF7, endoA, cyclin-G associated kinase, rab5, 
rab7L1, 14-3-3 (Hsu, et al., 2010; Chan, Citro, Cordy, Shen, & Wolozin, 2011; 
Hsu, Chan, & Wolozin, 2010; Gehrke, Imai, Sokol, & Lu, 2010; Beilina, et al., 
2014; Imai, et al., 2008; Matta, et al., 2012; Häbig, et al., 2013; Kumar, et al., 
2010; Nichols, et al., 2010; Shin, et al., 2008; Stafa, Trancikova, Webber, 
Glauser, West, & Moore, 2012; Ko, et al., 2009; Sancho, Law, & Harvey, 2009). 
LRRK2 has a regulatory role in a wide variety of biological processes; such as, 
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protein translations, cytoskeletal processes, vesicular dynamics, neurite 
extension, mitochondrial function, endoplasmic reticulum function and 
autophagy. Broad proteomics studies point to interactions with multiple new 
proteins, as well as regulation of many mitochondrial and lysosomal proteins (Di 
Domenico, et al., 2012; Beilina, et al., 2014). The multiple functions and 
pathways associated with LRRK2 suggest a complex role for LRRK2 in neuronal 
biology. We have approached this question by using systems biology to create a 
regulatory network that outlines the multiplicity of functional interactions of 
LRRK2 with its partners.  
We employed an in silico approach to elucidate the gene regulatory 
network linked to LRRK2 (Dusonchet, et al., 2014; Faith, et al., 2007). This 
approach used a network algorithm, termed The Context Likelihood of 
Relatedness (CLR) (Faith, et al., 2007). This algorithm is designed to analyze 
state-dependent genome-wide expression data based on the degree of 
synchrony in variation of transcript levels among samples.  Thus, transcripts 
whose expression varies in concert with LRRK2 transcripts are deemed 
neighbors. We analyzed both brain and white blood cells; use of white blood cells 
diversified the pathway representation away from a predominance of genes 
linked to cell death pathways, presumably because white blood cells are not 
post-mortem tissues. The LRRK2-centered association sub-network identified 
many known interactors, as well as many novel linked pathways (Dusonchet, et 
al., 2014). For instance, network proteins that have been previously associated 
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with LRRK2 are present in this network, including DJ-1, PINK1, MKK7 and JIP1 
(Ferree, et al., 2012; Hsu, et al., 2010; Hsu, Chan, & Wolozin, LRRK2 and the 
Stress Response: Interaction with MKKs and JNK-Interacting Proteins, 2010; 
Carballo-Carbajal, et al., 2010; Sancho, Law, & Harvey, 2009; Dusonchet, et al., 
2014; Ho, Rideout, Ribe, Troy, & Dauer, 2009). The network also identified many 
novel networks linked to LRRK2.  Subsequent studies validated the putative roles 
of these interacting proteins using knockdown studies in C. elegans.  
Previous work from the laboratory established that LRRK2 expression 
protects dopaminergic neurons against degeneration induced by the 
mitochondrial toxin, rotenone.  We tested the action of the putative network 
partners in LRRK2 mediated protection of dopaminergic neurons, and identified 
about 280 genes whose knockdown modified the effects of LRRK2 on 
dopaminergic neurons.  Genes whose knockdown impaired LRRK2 action 
included genes known to be part of the LRRK2 network (DJ-1, PINK1, MKK7 and 
JIP1), as well as multiple other genes, including HDAC6, vps34 and unc51, each 
of which is associated with autophagy (Dusonchet, et al., 2014). The connection 
between LRRK2 and autophagy is consistent with several other prior studies, as 
well as with studies suggesting a role for LRRK2 in vesicular biology (Plowey, 
Cherra, Liu, & Chu, 2008;Alegre-Abarrategui, et al., 2009; Biskup, et al., 2006). 
One particularly interesting proteins identified through the network 
analysis was the signaling gene RGS2 (regulator of G protein signaling 2), which 
encodes for a GTPase-activating protein (GAP), as a statistically significant 
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regulatory “hub” in the pathways linking LRRK2 with DJ-1, PINK1 and Parkin 
(Dusonchet, et al., 2014). RGS2 is also of particular interest because prior 
studies indicate strong expression in dopaminergic neurons.  This positioning of 
RGS2 as a “hub” for multiple genes linked to PD suggests a key role for RGS2 
as a regulator of LRRK2 activity, function and neuronal toxicity (Dusonchet, et al., 
2014). RGS proteins are a family of proteins characterized by a GAP domain of 
~130 amino acids, the RGS domain. Other GAP proteins have also been 
associated with LRRK2 function, including ArfGAP1 and ArhGEF7 (Häbig, et al., 
2013; Stafa, Trancikova, Webber, Glauser, West, & Moore, 2012; Xiong Y, Yuan, 
Chen, Dawson, & Dawson, 2012). Although GAPs and GTPase exchange factors 
(GEFs) are classically considered to function in regulating signaling of G-protein 
coupled receptors, these GAPs exhibit a strong role in regulating LRRK2 
GTPase activity. Recombinant RGS2 and ArhGEF7 increase the GTPase activity 
of immunopurified full-length LRRK2 in a dose-dependent manner in vitro. 
Recombinant RGS2 also inhibits the LRRK2 kinase activity in a dose-dependent 
manner. However, the concentration of RGS2 required to achieve maximal 
inhibition of LRRK2 kinase activity, occurs at one tenth of the concentration of 
RGS2 that is required to stimulate GTPase activity maximally.  It is increasingly 
clear that the output of LRRK2 is modulated by the particular GAP or GEF bound 
to it.  All of the GAPs and GEFs appear to increase LRRK2 GTPase activity, but 
RGS2 and ArhGEF7 reduce LRRK2 kinase activity, while ArfGAP1 increases 
LRRK2 autophosphorylation (Häbig, et al., 2013; Stafa, Trancikova, Webber, 
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Glauser, West, & Moore, 2012; Dusonchet, et al., 2014). This suggests that the 
output from the GTPase domain is determine, in part, by the particular GAP or 
GEF with which it is associated. 
 
 
 
Figure 5. Regulation of LRRK2 output by GTPase activity, GAPs and GEFs. 
RGS2 and ArhGEF7 both bind to LRRK2 and inhibit GTPase activity, which also 
inhibits LRRK2 kinase activity and appears to direct LRRK2 toward increasing 
neuronal cytoskeletal activity. Rac1 is a small GTPase known to regulate actin 
polymerase. Rac1 binds to LRRK2 and might act in concert with LRRK2 to 
increase cytoskeletal activity. In contrast, binding of ArfGAP1 to LRRK2 
increases its autophosphorylation, which appears to inhibit cytoskeletal activity. 
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GAPs and GEFs modulate cytoskeletal effects of LRRK2 
A putative role for LRRK2 in regulating cytoskeletal function consistently 
appears in the literature.  LRRK2 has been observed to regulate neurite 
outgrowth, tubulin and microtubules, trafficking proteins and actin (Chan, Citro, 
Cordy, Shen, & Wolozin, 2011; Hsu, Chan, & Wolozin, 2010; Caesar, Zach, 
Carlson, Brockmann, Gasser, & Gillardon, 2013; Law, et al., 2014). Our studies 
suggest that RGS2 inhibits the tendency of LRRK2 (WT and G2019S) to reduce 
length and complexity of neuronal processes in primary neurons (Figure 5, 
Dusonchet, et al., 2014). Co-expression of RGS2 with LRRK2 significantly 
protects against G2019S LRRK2-induced neurite shortening, although RGS2 
alone has no effect on axonal length. ArhGEF7 also increases LRRK2 GTPase 
activity but induces LRRK2 to increase neuronal arborization, length and growth 
cone formation (Figure 5, Dusonchet, et al., 2014; Häbig, et al., 2013). In 
contrast, knockdown of ArfGAP1 protects against G2019S LRRK2-induced 
neurite shortening (Figure 5, Dusonchet, et al., 2014; Stafa, Trancikova, Webber, 
Glauser, West, & Moore, 2012). ArhGEF7 acts through the actin cytoskeleton, 
which raises the possibility that it might act in tandem with rac1 and cdc42, both 
of which bind LRRK2 (Chan, Citro, Cordy, Shen, & Wolozin, 2011; Häbig, et al., 
2013). These data suggest that small GTPases and their regulatory proteins act 
to regulate the actions of LRRK2 on the cytoskeleton and neurite outgrowth 
(Figure 5, Dusonchet, et al., 2014).  Redundant actions of RGS2 and ArhGEF7 
towards neurite cytoskeletal activity seems unlikely, which raises the possibility 
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that RGS2 and ArhGEF7 exhibit divergent effects on LRRK2 when examining 
other functions, such as vesicular biology.  
 
Conclusions 
LRRK2 is a large molecule with many molecular interactions. Multiple 
studies have focused on its kinase activity, with the resulting identification of 
LRRK2 inhibitors that might have therapeutic benefit.  The function of LRRK2 
kinase activity remains unclear, with LRRK2 itself being the most robust 
substrate identified to date.  Meanwhile, LRRK2 has been shown to interact with 
many different proteins, suggesting that important function of LRRK2 might lie in 
domains linked indirectly or not at all to its kinase function.  A recent study 
suggests that an important action of phosphorylation is regulation of LRRK2 
degradation, which would imply that one must look beyond kinase function to 
understand the role of LRRK2 in the neuron (Skibinski, Nakamura, Cookson, & 
Finkbeiner, 2014). The need to look beyond kinase function is emphasized by 
examination of the actions of GAPs and GEFs on LRRK2, where proteins that 
exhibit seemingly similar actions towards LRRK2 kinase activity elicit opposite 
actions on regulation of neurite outgrowth and cytoskeletal function (Figure 5, 
Dusonchet, et al., 2014). 
Studies from our laboratory and other laboratories have identified 
numerous other signaling molecules that interact with LRRK2. The interactions of 
LRRK2 are clearly pleiotropic, and vary depending on the cell type and the 
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function being investigated.  Despite this complexity, several distinct themes are 
evolving, and these themes potentially have important implications for our 
understanding of the pathophysiology of PD.  One theme that arises is the role of 
LRRK2 in regulating signaling cascades, such as the MAPK cascade.  It is clear 
that LRRK2 acts in a manner that is different than classic modulators of the 
MAPK cascade, because it does not directly stimulate phosphorylation of MAP 
Kinases. The large size of LRRK2 enables it to bind multiple different proteins, 
and potentially bring them together as a signaling scaffold, analogous to JIPs. 
A general theme occurring throughout the field of Parkinson’s disease is 
regulation of vesicular transport.  The vast majority of genes associated with PD 
have some function related to membranes and vesicles.  α-Synuclein is thought 
to regulate production of small vesicles by promoting membrane curvature 
(Ducas & Rhoades, 2012; Perlmutter, Braun, & Sachs, 2009; Varkey, et al., 
2010). LRRK2 also shows strong interactions with membranes and is thought to 
modulate autophagy, which also involves vesicular dynamics.  PINK1, parkin and 
HTRA2 are all proteins that regulate mitochondrial function, possibly including 
mitophagy (Narendra, et al., 2010; Plun-Favreau, et al., 2007). ATP13A2 and 
GBA are both associated with lysosomes (Mazzulli, et al., 2011; Usenovic, et al., 
2012). The consistent appearance of vesicular biology in the pathophysiology of 
PD suggests that interactions of LRRK2 with vesicles are likely to contribute to its 
mechanism of disease pathogenesis.  Future studies will need to specifically 
investigate how signaling pathways regulate the interactions of LRRK2 with 
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membranous organelles, such as autophagosomes.  In this context, the 
preliminary data showing roles for the MAPK cascade in regulating the 
interactions of LRRK2 with the autophagic system are intriguing (Plowey, Cherra, 
Liu, & Chu, 2008). 
The complexity of LRRK2 signaling provide insight into the nature of 
pathology associated with LRRK2-mediated disease.  Most cases with LRRK2 
mutations exhibit α-synuclein pathology, such as Lewy bodies, but some cases 
exhibit tau pathology (Devine & Lewis, 2008). This pathological heterogeneity 
might derive from the impact of different disease processes on LRRK2 biology, 
with some signaling cascades (such as MAPKs) promoting tau pathology and 
other signaling cascades (such as vesicular biology) promoting α-synuclein 
pathology.  
 
Translational Regulation  
 
These previous studies demonstrated the importance of LRRK2 and α-
synuclein in PD. However, the mechanisms underlying the cause and 
development of PD remain unclear. There are two mechanisms in particular that 
LRRK2 has been shown to be involved in and these two mechanisms have 
potential linkages to the translational regulation of α-synuclein. One of these 
mechanisms is the 4E-BP-mediated pathway in protein translation and the other 
one is the micro-RNA-mediated regulation pathway of translation. LRRK2 has 
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been shown to have a role in translation through its interaction with eIF4E-
binding protein (4E-BP), which can lead to an enhancement in translation (Imai, 
et al., 2008; Doral & Hébert SS, 2012). On the other hand, LRRK2 has also been 
shown to interact with the microRNA (miR) pathway to regulate protein synthesis, 
where it associates with the RISC and negatively regulates miRs (Gehrke, Imai, 
Sokol, & Lu, 2010). MiRs can bind to target 3’UTRs, such as the short and long 
3’UTR of the α-synuclein transcripts, and regulate translation of the 
corresponding transcripts (Chen & Rajewsky, 2007; Bartel, 2009; Kusenda, 
Mraz, Mayer, & Pospisilova, 2006). Thus, we were curious to investigate how 
LRRK2’s implication for translational regulation through the miRs can affect α-
synuclein protein translation and expression.  
 
Translational Regulation via MiRs and the RNA-induced silencing complex  
MiRs Characteristics and Functions 
MiRs are small 19-23 RNA nucleotides, which function in transcriptional 
and post-transcriptional regulation of gene expression (Chen & Rajewsky, 2007). 
MiRs function through base-pairing with complementary sequences within 
mRNA, which result in silencing these mRNA strands as they are no longer able 
to be translated into proteins by ribosomes and are degraded by the cell. This 
regulation of gene expression by miRs is mediated through the RNA-induced 
silencing complex (RISC). The RISC-mediated mRNA sequestration and 
translational repression is by miRs binding minimally to complementary “seed” 
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sequences in the 3’untranslated regions (UTR) of the target mRNAs (Bartel, 
2009; Kusenda, Mraz, Mayer, & Pospisilova, 2006). The RISC is a multi-protein 
complex, which incorporates one strand of miR or siRNA (small interfering RNA) 
and uses that strand as a template for complementary mRNA. Upon the binding 
of the complementary strand mRNA, Argonaute, which is a protein within the 
RISC, will then be activated and cleaved the RNA. This process is essential for 
both gene regulation via miRs and also in defense against viral infections, which 
frequently employ double-stranded RNA as infectious vectors (Watson, 2008). 
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Figure 6. Translational regulation via miRs and the RNA-induced silencing 
complex. The RISC complex incorporates one strand of miR as a template for 
complementary mRNA through base-pairing. Upon the binding of the 
complementary strand mRNA, Argonaute within the RISC will be activated and 
cleave the RNA.  
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LRRK2 regulation of miRNA-mediated translation regulation 
LRRK2 has been shown to interact with the miR pathway to regulate 
protein synthesis, where it associates with the RISC and negatively regulates 
miRs (Gehrke, Imai, Sokol, & Lu, 2010). Studies have shown that LRRK2 binds 
to and phosphorylates 4E-BP, which then activates 4E-BP for subsequent 
phosphorylation by 4E-BP kinase (Imai, et al., 2008). Phosphorylated 4E-BP will 
then dissociate from eukaryotic translation initiation factor 4E (eIF4E) (Imai, et 
al., 2008; Doral & Hébert SS, 2012).  
Furthermore, studies have suggested that phosphorylated 4E-BP by 
LRRK2 can bind to eukaryotic translation initiation factor 2C (eIF2c) and 
Argonaute, which are proteins that are central to the RISC function and are 
needed to the miRs-induced silencing of mRNA. Additionally, G2019S, PD-
associated mutant variant of LRRK2, has an increased kinase activity and can 
further stimulate the interaction between phosphorylated 4E-BP with Argonaute, 
which affect the miRNA pathway in ways such as increase affinity for eiF2c/Ago, 
upregulation of protein translation, and abnormal gene transcription. This may in 
turn results in over-stimulation of protein synthesis, leading to various 
consequences, such as protein aggregation, cell stress, and ultimately, cell death 
(Doral & Hébert SS, 2012). Further investigations of these studies are needed. 
Nevertheless, these studies shed light on the crosstalk between LRRK2 and 
miRs. 
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Figure 7. Hypothetical model of LRRK2 regulation of miR-mediated translational 
regulation. LRRK2 binds to and phosphorylates 4E-BP1. Phosphorylated 4E-BP1 
then binds to eiF2c/Ago, which can potentially modulate miRNA binding to its 
mRNA targets and affect gene expression (Adapted from Imai, et al., 2008 and 
Doral & Hébert SS, 2012). 
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However, other studies have suggested that 4E-BP is a relatively 
poor direct substrate for LRRK2 (Kumar, et al., 2010). Kumar, et al. (2010) 
showed that LRRK2 is capable of phosphorylating 4E-BP in vitro and 
G2019S was approximately 2 fold more active than wild-type LRRK2. 
However, with inducible expression of LRRK2 in HEK cell lines, Kumar, et 
al. (2010) did not see changes in 4E-BP phosphorylation levels and yet 
MAPK14/p38alpha could efficiently phosphorylate 4E-BP at the same site 
as LRRK2 in vitro, which lead to their suggestion that the increased 4E-BP 
phosphorylation in some systems may be related to p38-mediated cell 
stress rather than direct LRRK2 activity.  
 
Specific MiRs relevant to PD that bind to α-synuclein transcripts 
Recent studies have shown specific miRs that are relevant to PD. Studies 
have found that miR-133b is deficient in the midbrains of PD patients and in 
mouse models of PD. Whereas, miR-34b/34c has a decreased level in several 
affected brain regions in PD patients and LB diseases patients (Mouradian, 
2012). Studies have also demonstrated that at least two miRs, miR-7 and miR-
153, have negative control of α-synuclein mRNA (Mouradian, 2012). Studies 
have shown that over-expression of miR-7 and miR-153 significantly reduces 
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endogenous α-synuclein levels, whereas inhibition of miR-7 and miR-153 
enhances translation of α-synuclein.  
 
Hypothesis 
As mentioned previously, LRRK2 has been shown to interact with the miR 
pathway to regulate protein synthesis, where it associates with the RISC and 
negatively regulates miRs (Gehrke, Imai, Sokol, & Lu, 2010). In addition, studies 
have demonstrated polymorphisms in the 3’UTR of α-synuclein mRNAs, which 
are where the binding sites of miRs located (Mouradian, 2012; Rhinn, et al., 
2012). Thus, the effects of miRs on α-synuclein may vary based on which 
polymorph of 3’UTR that the α-synuclein mRNA carries.  
 Henceforth, in our study, we hypothesize that the LRRK2 regulates α-
synuclein expression post-transcriptionally via miR with implications for PD. 
 In Aim 1, we determined if LRRK2 regulates α-synuclein protein 
expression differentially based on the length of α-synuclein’s mRNA transcript 3’ 
UTR.  
 In Aim 2, we determined if LRRK2 effects on α-synuclein protein 
expression regulation requires the binding of miRs. 
 In Aim 3, we determined if the kinase activity of LRRK2 is essential for its 
regulation of α-synuclein protein expression.  
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CHAPTER 2: MATERIALS AND METHODS 
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Constructs 
Plasmids expressing C-terminal enhanced green fluorescent protein 
(EGFP)-tagged α-synuclein constructs with short or long 3’UTR were provided by 
Dr. Asa Abeliovich, Columbia University, New York (Rhinn, et al., 2012).  
N-terminal 2X-Myc-tagged full-length human LRRK2 plasmids (WT, 
G2019S and R1441C) were kindly provided by Dr. Mark Cookson (National 
Institutes of Health, Bethesda, MD, USA; Greggio, et al., 2006).  
 
MiR Mimics and Inhibitors  
MiR-7 and miR-153 mimics and inhibitors were order-made through Life 
Technologies.  
 
Site-Directed Mutagenesis 
Site-directed mutagenesis was used to introduce point mutations at the 3’ 
untranslated region (UTR) of α-synuclein gene. The mutagenesis experiments 
were performed with the QuikChange II Site-Directed Mutagenesis Kit by Agilent 
Technologies according to the manufacturer’s protocol. The site-directed 
mutagenesis was targeted at the binding sites of miR-7 and miR-153 in the 3’ 
UTR of α-synuclein gene. Samples were prepared as follow: 10 ng of dsDNA 
template, 125 ng of primer #1 and 125ng of primer #2, 5 µl of 10X Reaction 
Buffer, 1 µl of dNTP mix, with ddH2O to 50µl. Then 1 µl of PfUltra Hf DNA 
Polymerase (2.5 U/µl) was added to each sample. Polymerase chain reaction 
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(PCR) using a denaturing temperature of 95oC and an elongation time of 16 
minutes at 68oC was performed for a total of about 3 hours. After mutagenesis, 
the PCR products were digested with 1 µl DnpI endonuclease, at 37oC for 1 hour 
to remove any remaining parental DNA. Digestion was followed by 
transformation into One Shot Top10 competent cells (Invitrogen) to screen for 
DNA containing the desired mutation.  
 
Restriction Enzyme Digest 
Restriction enzymes and accompanying buffers (New England Biolabs, 
NEB) were used to excise vectors and inserts from DNA for ligation and to 
confirm that plasmids contained the correct cDNA. Buffer conditions were chosen 
based on information gathered from the NEB website Double Digest Finder. 
Approximately 1 µg of DNA was mixed with 1µl of the appropriate restriction 
enzymes and 3µl of 10x buffer. The mixture was brought up to 30µl with HyClone 
HyPure Molecular Biology Grade water (ThermoFisher) and incubated at 37oC 
for 30 minutes – 1 hour for complete digestion.  
 
Agarose DNA Gel Electrophoresis 
Samples were run on agarose gel electrophoresis in order to separate 
restriction enzyme products by molecular size in order to confirm that plasmids 
contained the correct cDNA. 0.8% Agarose gel was made from Genepure LE 
Quick Dissolve Agarose (ISC BioExpress) in 1 X Tris-Acetate-EDTA (TAE) 
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buffer. The mixture of agarose and TAE was heated in a microwave to ensure all 
agarose was dissolved. The solution was allowed to cool off and 1 µl of Ethidium 
Bromide (EtBr) is added to the solution, which allows the visualization of DNA 
fragments. The mixture is then transferred to a gel casting tray with a comb in 
place to make the wells for sample loading. The mixture cools down in the tray 
and the gel solidified. 1 X TAE is poured into the gel box, covering the gel. DNA 
samples are added with 2 µl of Blue Loading Dye (Promega) and 12-15 µl of the 
mixture is loaded into each well of the gel. A 1kb ladder (Promega) is also loaded 
in a separate well to run alongside of the samples in order to identify the 
molecular weights of each band. The samples are then separated by 
electrophoresis for 30 minutes at 150V. The bands are then visualized under an 
UV light box.  
 
DNA Sequencing 
The sequences of all cloned plasmids were verified by GENEWIZ and 
Vector NTI.  
 
Plasmid DNA Preparation 
Bacterial Transformation 
Plasmid DNA was introduced into competent bacterial cells through 
bacterial transformation in order to screen for successfully cloned plasmids 
containing specific antibiotic resistance genes that allow their growth on plates 
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supplemented with the same antibiotic, kanamycin, for both 2 x myc LRRK2 and 
EGFP-α-synuclein. Plasmid DNA was transformed into One Shot Top Ten 
Competent E. Coli cells (Invitrogen) through the heat shock method. 6 µl-50µl of 
Top Ten cells were incubated with 1-10 µg of plasmid DNA on ice for 30 minutes. 
The samples were then heat shocked at 42oC for 40 seconds and placed back 
on ice for 2 minutes. 250 µl of 1X S.O.C. Medium (Invitrogen) was then added to 
the cells and cells were incubated in a shaker at 225 rpm at 30oC or 37oC for 1 
hour. The cells were then spread onto agar plates made with LB-Agar (MP 
Biomedicals) and supplemented with the specific antibiotic (kanamycin) that the 
cloned plasmid carried resistance genes to and the plates were allowed to air dry 
in the sterile cell culture hood. When the plates were dried, they were incubated 
in a 30oC or 37oC, depending on the specific plasmid, incubator overnight for 
colony formation.  
 
Miniprep 
Plasmid DNA is extracted and purified by miniprep at a small scale. 
Transformed bacterial colonies were selected from agar plates the next day after 
bacterial transformation and incubation, and were transferred into 4 mL of LB 
broth containing 0.5 mg/mL kanamycin. The inoculations were incubated 
overnight in a shaker at 225 rpm, at 30oC or 37oC. DNA was then purified from 
the bacterial culture by the QIAprep Spin Miniprep kit (Qiagen) according to the 
manufacturer’s protocol. The DNA can be stored at -20oC until use. 
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Midiprep 
Similar to minipreps, midipreps were used to extract and purify plasmid 
DNA, but at a larger scale. 100 mL of LB broth with antibiotic was used for 
inoculations in a shaker at 225 rpm, at 30oC or 37oC overnight. On the next day, 
DNA was purified from the bacterial culture using the QIAprep Spin Midiprep kit 
(Qiagen) according to the manufacturer’s protocol. The DNA is stored at -20oC 
until use. 
 
Maxiprep 
With same concept as miniprep and midiprep, plasmid DNA is extracted 
and purified at a large scale. A single colony from an agar plate containing the 
transformed bacteria was picked at the end of the day after transformation and 
incubation into a 5 mL LB mini-culture tube and was incubated in a shaker at 225 
rpm, at 30oC or 37oC for overnight. On the next day, the 5mL culture was 
transferred into a 300 mL culture in a large flask and incubated the flask in a 
shaker at 225 rpm, at 30oC or 37oC overnight. On the following day, DNA was 
purified from the bacterial culture using the Maxiprep kit (Clontech) according to 
the manufacturer’s protocol. The DNA is stored at -20oC until use. 
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DNA Spectrophotometry 
After elution of DNA from mini/midi/maxiprep, DNA concentration and 
integrity was determined by Nanodrop. Absorbances were read at 260 nm, 280 
nm and 230 nm. The measurement at 260 nm was to determine the 
concentration of DNA, the measurement at 280 nm was to determine the 
concentration of protein contaminants, and the measurement at 230 nm was to 
determine the concentration of RNA contaminants. The 260/280 and 260/230 
ratios estimate the purity of the DNA samples and the samples were considered 
pure if the ratio was between 1.8 and 2.0.  
 
Cell Culture 
Human Embryonic Kidney (HEK)-293 FT cells were cultured in Corning 75 
cm2 canted neck, non-pyrogenic, polystyrene flask. Cells were maintained in 10 
ml media consisting of Dulbecco’s modified Eagle’s media (DMEM) 1 X with L-
glucose, L-glutamine and sodium pyruvate (Corning CellGro) supplemented with 
10% fetal bovine serum (FBS) (Atlanta Biologicals), 1% nonessential amino aids 
and 1% penicillin and streptomycin (100µg/ml) (Gibco by Life Technologies) and 
1% L-glucose (2 mM) (Gibco by Life Technologies) at 37oC and 5% CO2. Cells 
are grown in the flask and when the confluency reaches 70-80%, which normally 
takes about 3 to 4 days, the cells are split. To split cells, cells are first washed 
gently with 5 ml of Dulbecco’s Phosphate Buffered Saline (DPBS) (1X) (Gibco by 
Life Technologies) and then cells were incubated in 5 ml of 0.25% Trypsin-EDTA 
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(1X) for 1 minute to remove cell adhesion proteins. Flask is gently rocked back 
and forth to detach cells from the flask’s surface. The cell suspension is then 
transferred into a 50ml centrifuge Falcon tube (BD Falcon) that contains 10ml of 
growth media with serum to neutralize the trypsin. Cells are spun down in 
(Sorvall Legend Mach 1.6R) at 1000 rpm for 4 minutes at 4oC. The supernatant 
is removed and the cells are re-suspended in 10 ml of growth medium.  
Cells are stained with Trypan Blue (0.4%) (Sigma) and counted under the 
microscope and 2 million cells are placed into a new Corning 75cm2 canted neck, 
non-pyrogenic, polystyrene flask where growth medium is used to bring up the 
total volume in the flask to 10 ml for cells to propagate as the next passage. 
Cells can also be frozen for storage, which is usually done at earlier 
passage number; for example, passage 1, 2 or 3. Cells are washed with DPBS, 
trypsinized and centrifuged as described for the cells splitting procedure. Cells 
are resuspended in growth media and counted with Trypan Blue. Cells are then 
spun down again and this time, cells are resuspended in freezing medium, which 
consists of 70% DEMEM, 20% FBS and 10% dimethyl sulfoxide (DMSO), with a 
concentration of 1 million cells per ml. Then 1 ml aliquots of this resuspension 
are transferred to cryogenic tubes (Corning), which are placed within an 
isopropanol bath at -80oC overnight. On the next day, the cryogenic tubes are 
transferred to a liquid nitrogen tank for long-term storage until demand.  
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Transfection of HEK-293 FT Cells 
 Plasmid DNA was introduced into mammalian cells through transient 
transfection. During cell division, the plasmid will amplify and the desired DNA 
product will be synthesized in large quantities. Transfection agent, Lipofectamine 
2000 (Invitrogen, Life Technologies) is employed to deliver the plasmid DNAs 
into cells according to the Lipofectamine 2000 protocol (Invitrogen, Life 
Technologies).  
 Cells were plated 24 hours before transfection at a confluency that will 
reach 70-80% 24 hours later at the time of transfection. The amount of 
Lipofectamine 2000 needed for transfection is based on the amount of DNA 
being transfected in the ratio of 2.5 to 1, Lipofectamine 2000 (µl) to DNA (µg). 
Lipofectamine 2000 is first activated in Opti-MEM for 5 minutes, then the desired 
plasmid DNA in Opti-MEM is added into the lipofectamine 2000 Opti-MEM mix in 
a 1:1 ratio of volume and allowed to incubate for 20 minutes. Then, the 
transfection mix is added to the plated cells. Twenty-four hours after transfection, 
data are collected from the cells.  
MicroRNA mimics and inhibitors were transfected into HEK-293 FT with 
Lipofectamine RNAiMAX Reagent according to the protocol from Invitrogen, Life 
Technologies.  
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Fluorescence Visualization of GFP-tagged α-synuclein 
HEK-293 FT cells were visualized with an Olympus IX50 microscope. 
Fluorescence of EGFP-tagged α-synuclein in HEK-293 FT was verified under the 
microscope (10X). 
 
Quantification of Fluorescence of GFP-tagged α-synuclein 
Expression levels of α-synuclein in HEK-293 FT were quantified by 
FLUOstar Optima by BMG Labtech spectrometer, controlled for background 
fluorescence. The spectrometer was set with excitation wavelength at 490 nm 
and emission wavelength at 510 nm. 
 
Western Blotting 
Cell Lysates Preparation of HEK-293 FT Cells 
Cell Lysates were collected and prepared for protein analysis to show 
equal amount of expression of certain transfected plasmid as a control. 
Transfected cells were washed with 1 X DPBS and were lysed with Lysis buffer, 
consisting Phosphate Buffered Saline (PBS), 0.5% Triton X-100, protease 
inhibitor and phosphatase inhibitor. Lysates were scraped and collected by 
disposable cell lifter (Fisher Scientific) and pipetted into 1.5 ml Eppendorf tubes. 
Samples were then rotate on a Rotisserie at 4oC for 1 hour, followed by 
centrifugation at 13,200 rpm at 4oC, for 10 minutes. The supernatant was 
transferred and collected into an Eppendorf tube and stored at -20oC until use.  
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Bicichoninic Acid (BCA) Assay 
Protein concentrations of cell lysates were determined by the BCA protein 
assay kit (Pierce) and BCA analysis. The BCA assay is a colormetric assay 
which is based on the reduction of copper ions to cuprous ions by proteins in an 
alkaline media and the cuprous ions are detected by the chelation with two 
molecules of BCA, forming a product that is purple and can be detected in a 
spectrometer at a wavelength of 490 nm. A set of standards with known 
concentrations is pipetted into the same 96-well plate as the samples with 
concentrations to be determined. The standards with known concentrations will 
then provide a standard curve of the amount of absorbance at wavelength 
490nm respective to each concentration. The concentration of each sample can 
be determined from the standard curve.  
 
Sodium Dodecyl Sulfate (SDS) Polyacrylamide Gel Electrophoresis 
Proteins are separated by molecular weight by SDS Polyacrylamide Gel 
Electrophoresis (PAGE). 4-20% Tris-Acetate gels were purchased from Novex, 
Invitrogen Sample Reducing Agent (NuPAGE Invitrogen) and LDS Sample Buffer 
(NuPAGE Invitrogen) are added to twenty micrograms of proteins. The sample 
mixes are placed in a 95oC heat block for 5 minutes and are spun down at 
13,200 rpm for one minute at 4oC. The sample mix is loaded into each well of the 
gel in Tris-Acetate SDS Running Buffer (Novex, Life Technologies). Biorad’s 
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Precision Plus Protein Standards: Dual Color and Kaleidoscope Prestained 
Standards are loaded in two individual wells as a protein ladder to estimate the 
molecular weight of the visualized protein bands. Samples on the gel were 
separated in running buffer at 150 volts for about 90 minutes as the samples ran 
down the gel and approached the bottom of the gel.  
 
Protein Transfers 
After separation by SDS-PAGE, proteins were then transferred to BioRad 
Immuno-PVDF (membrane for protein blotting), sandwiched in between Biorad 
Mini Trans-Blot filter papers, surrounded by sponges, all submerged in NuPAGE 
Transfer Buffer with methanol at 40 volts for 2 hours at 4oC or in an ice bucket.  
 
Western Blots 
The presence of separated proteins on the blot was detected by specific 
antibodies. The blot was first washed by TBST (50mN Tris, 150mM NaCl and 
0.1% (v/v) Tween 20), 3 times, 5 minutes each wash at room temperature. Then, 
the blot was blocked by 5% milk, which is non-fat dry milk powder in TBST for 1 
hour at room temperature. After blocking with milk, the blot was incubated in 
primary antibody overnight at 4oC on a shaker. On the next day, the membrane 
was washed with TBST 3 times and 10 minutes for each wash at room 
temperature. Secondary antibody is added to the blot and the blot is incubated 
for 1 hour on a shaker at room temperature. After the secondary antibody 
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incubation, the blot was washed three times with TBST for 10 minutes at room 
temperature. The Supersignal West Pico Chemiluminescent Substrate (Thermo 
Scientific) was then added to the membrane for 5 minutes and the blot was 
developed on JyBlot CL Autoradiography Film by Denville Scientific, Inc. or 
visualized by BioRad Imager.  
  
Primary Cultured Neurons 
Primary cortical and hippocampal cultures were generated from embryonic 
day 18 (E18) progeny from pregnant Sprague-Dawley rats from Charles River 
Laboratories. Pregnant rats were killed by inhalation of CO2. Embryos were then 
collected by cesarean section. Both males and females embryos were used. 
Cortices and hippocampi were dissected and collected separately in Calcium and 
Magnesium Free (CMF) solution containing 10% Hank’s Balanced Salt Solution 
buffered with HEPES (HBSS) (Gibco), 42nM sodium bicarbonate (Sigma), 1mM 
Pyruvate (Sigma), 20mM Hepes (Sigma) and 3mg/ml Bovine Serum Albumin 
(BSA), in Hyclone H2O (Invitrogen), pH 7.25-7.30, and were digested with 0.25% 
trypsin for 9 minutes at 37oC, followed by trituration. Dissociated neurons were 
plated on glass coverslips pre-coated with poly-D lysine (100 µg/mL) (18 mm 
round glass coverslips (Warner Instruments) and placed in plating medium, 
which consists of neurobasal medium (Invitrogen) supplemented with 10% fetal 
bovine serum (FBS), 1% penicillin/streptomycin (100 µg/ml) and 0.5 mM of L-
Glutamine. After 2 to 3 hours of incubation, neurons were attached to cover 
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glasses and the medium was replaced by feeding medium, consisting neurobasal 
medium (Invitrogen) with 2% B27 supplement, 1% penicillin/streptomycin (100 
µg/ml) and 0.5mM of L-Glutamine. Neurons were grown in feeding medium at 
37oC, 5% CO2.  
 
Neuronal Transfection 
Primary neurons were transiently transfected with plasmid DNA using the 
transfection reagent Lipofectamine 2000 (Invitrogen, Life Technologies) at 5-6 
days in vitro (DIV). On DIV 5, Lipofectamine is first activated in neurobasal 
medium for 5 minutes. DNA plasmids/lipofectamine solution was prepared with a 
ratio of 1 µg: 4 µl and was incubated for 15 minutes at room temperature before 
adding to primary neurons. Neurons were incubated at 37oC, 5% CO2 for 20 
minutes, and the solution was then replaced by feeding media. This procedure 
was repeated on DIV 6 to enhance transfection efficiency. At DIV 7 or 10 or 21, 
neurons were fixed in 4% paraformaldehyde for immunostaining and microscopy.  
 
Immunocytochemistry 
On DIV 7 or 10 or 21, the transfected cells were washed once with cold 1x 
PBS and were then fixed with 4% paraformaldehyde in 1x PBS for 12 minutes at 
room temperature. The neurons were then washed 3 times with 1x PBS for 5 
minutes each. After the washes, the neurons were permeabilized with 0.1% triton 
X-100 in PBS for 15 minutes at room temperature. The neurons were washed 3 
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times with 1x PBS for 5 minutes each and were then incubated in blocking 
solution of 5% BSA for 1 hour at room temperature (RT). After blocking, neurons 
were incubated with 1:400 dilution of anti-c-myc (mouse, Sigma-Aldrich) or 
1:1000 anti-MAP2 (mouse) antibodies for overnight in 4oC. On the next day, 
neurons were washed 3 times with 1 X PBS for 5 minutes each at room 
temperature and were then incubated with 1:700 dilution of Alexa-594 donkey 
anti-mouse antibody (Jackson ImmunoResarch) in 1 X PBS for 1 hour at RT. The 
neurons then had a final wash step which consisted of 3 times with 1 X PBS for 
10 minutes each at room temperature. Then the coverslips were mounted on 
glass slides (Superfrost Plus Fisher Scientific) embedded in Prolong Gold Anti-
fade DAPI gel mounting medium (Invitrogen). Alternatively, at the third wash with 
1 X PBS after secondary antibody, DAPI stain at a concentration of 1:10,000 can 
be used to stain the nuclei, followed by a fourth wash with 1 X PBS for 10 
minutes at room temperature. Then, the coverslips are mounted on glass slides 
with ProLong Gold mounting medium without DAPI (Invitrogen). 
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Primary Antibody Anti-C-Myc Anti-MAP2 
Species Mouse Mouse 
Company Sigma-Aldrich Fisher Scientific 
Blocking 5% BSA, 1hr, RT 5% BSA, 1hr, RT 
Dilution 1:400, 5% BSA 1:700, 5% BSA 
Incubation Overnight, 4oC Overnight, 4oC 
Secondary Antibody Alexa-594 Donkey Anti-
Mouse 
Alexa-594 Donkey Anti-
Mouse 
Company Jackson ImmunoResarch Jackson ImmunoResarch 
Dilution 1:700, 5% BSA 1:700, 5% BSA 
Incubation 1hr, RT 1hr, RT 
 
Table 2. Primary and secondary antibodies used in ICC. 
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MitoTracker 
MitoTracker Red FM (ThermoFisher) is a far red-fluorescent dye with 
absorbance and emission of ~581/644 nm, which stains mitochondria in live cells 
and its accumulation is dependent upon membrane potential. The cell-permeant 
mitoTracker probes contain a mildly thiol-reactive chloromethyl moiety for 
labeling mitochondria in live cells. To label mitochondria, a MitoTracker probes 
stock solution of 1 mM final concentration was prepared with dimethylsulfoxide 
(DMSO) and was diluted to a working concentration between 100-500 nM (300 
nM in HEK-293 FT, 400 nM in neurons). Cells or neurons are then incubated with 
the probes, where the probes passively diffuse across the plasma membrane 
and accumulate in active mitochondria. After staining, the cells are washed in 
fresh, pre-warmed growth medium. Once mitochondria are labeled, the cells can 
be imaged as live-cells or fixed. Most of the MitoTracker probes are well-retained 
after fixation and permeabilization during subsequent processing steps, such as 
immunocytochemistry.  
 
Neuronal Imaging  
Olympus B60 Upright Microscope (AxioCam) (40X) and Zeiss (20X, 40X, 
63X) were used to visualize the expression, accumulation and localization of α-
synuclein, mitochondria, and dendritic processes in primary culture neurons and 
the morphology of neurons under different transfection conditions (40X). On 
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average, 50 processes from 15 different neurons in each group were analyzed. 
All images were processed by ImageJ and NeuronJ software and Adobe 
Photoshop CS2.  
 
Neurite Length Quantification 
Neurite processes from neurons stained with DAPI for nuclei, and positive 
for EGFP-α-synuclein were stained with microtubule-associated protein 2 
(MAP2) by immunocytochemistry and were quantified using the PlugIn NeuronJ 
macros for ImageJ.  
 
Statistical Analysis 
All data were analyzed by Prism (GraphPad). One-way ANOVA and 
Tukey’s post hoc tests were ran to test and determine any statistically significant 
differences among datasets. All data were expressed as mean ± SEM and were 
graphed by using Microsoft Excel.  
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CHAPTER 3: LRRK2 REGULATES α-SYNUCLEIN PROTEIN EXPRESSION 
POST-TRANSCRIPTIONALLY VIA MIRS 
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Post-Transcriptional Regulation of α-Synuclein by LRRK2 
 
Adapted from Boon JY, Abeliovich A, Wolozin B. Post-Transcriptional Regulation 
of α-Synuclein by LRRK2 (in preparation) 
 
Abstract 
α-Synuclein is a small protein that accumulates and aggregates to form 
Lewy bodies, one of the major hallmarks of Parkinson’s disease (PD). Mutations 
in the α-synuclein gene can lead to autosomal dominant familial PD. Recent 
studies have shown that there are various transcript isoforms of α-synuclein 
varying in length of its 3’ untranslated region (UTR). 3’ UTR is a target region for 
RNA binding proteins and microRNAs (miRs) in regulating protein translation 
from mRNA transcript. The most common genetic cause of PD, Leucine-rich 
repeat kinase 2 (LRRK2), has been shown to have a role in protein translation. 
This leads to our hypothesis that LRRK2 post-transcriptionally regulates α-
synuclein protein expression via miRs. In the absence of LRRK2, α-synuclein 
mRNA with short 3’ UTR has similar protein expression level to that with long 3’ 
UTR. Wild-type LRRK2 and disease mutant G2019S increase α-synuclein 
protein expression in HEK-293FT cells, particularly a greater increase for the α-
synuclein transcript isoform with short 3’ UTR relative to the long 3’ UTR isoform. 
Similarly, in rat primary hippocampal neurons, wild-type LRRK2 and G2019S 
lead to a greater accumulation and broader distribution of α-synuclein along the 
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neuronal processes. These differential effects of LRRK2 on α-synuclein are 
dependent on the binding of miR-7 and miR-153 to the 3’ UTR of the α-synuclein 
isoforms, where the short isoform has binding site for miR-7only and the long 
isoform has bindings sites for miR-7 and miR-153, and require the kinase activity 
of LRRK2. These findings highlight novel regulations of α-synuclein protein 
expression by LRRK2 via miR, in particular with miR-7 as the stronger mediator, 
and suggest miRs as potential targets for interfering with α-synuclein neuronal 
accumulation.  
 
Introduction 
Protein aggregation and accumulation is a hallmark of many 
neurodegenerative diseases. One of the major neuropathological hallmarks of 
Parkinson’s disease  (PD) is the intracellular proteinaceous inclusions called 
Lewy Bodies (LB) (Alim, et al., 2002; Popescu, Lippa, Lee, & Trojanowski, 2004; 
Ferree, et al., 2012; Wakabayashi & Takahashi, 2000). α-Synuclein is a major 
component of LBs and are in the form of hyperphosphorylated and ubiquitinated 
aggregates and insoluble filaments (Spillantini, Crowther, Jakes, Hasegawa, & 
Goedert, 1998; Hasegawa, et al., 2002). This leads to the hypothesis where 
abnormal protein aggregation may lead to neuronal death in PD (Trojanowski, 
Goedert, Iwatsubo, & Lee, 1998). 
Mutations in the SNCA gene can lead to autosomal dominant PD, where 
patients display early disease onset with atypical symptoms such as myoclonus 
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and more severe autonomic dysfunctions (Spira, Sharpe, Halliday, Cavanagh, & 
Nicholas, 2001; Li, Uversky, & Fink, 2001; Polymeropoulos, et al., 1997). Current 
studies have shown that increased SNCA gene dosage may lead to earlier 
disease onset and severity in wild-type α-synuclein mouse models and this was 
in concordance with the identification of families with duplicates or triplicates of 
the wild-type α-synuclein gene (Nishioka, et al., 2006; Singleton, et al., 2003). In 
addition, studies have shown that mutant α-synuclein can inhibit chaperone-
mediated autophagy (CMA), which can block its own degradation and other 
substrates (Cuervo, Stefanis, Fredenburg, Lansbury, & Sulzer, 2004). 
Recent studies have suggested that specific RNA transcript isoforms of α-
synuclein with an extended 3’ untranslated region (UTR) are selectively linked to 
Parkinson’s pathology (McLean, Hallett, Cooper, Stanley, & Isacson, 2012). 
Studies have also suggested that α-synuclein with long 3’UTR relative to α-
synuclein with short 3’UTR are more toxic. Rhinn et al. (2012) has showed that 
the presence of the extended 3’UTR of α-synuclein transcript promoted the 
accumulation and translation of α-synuclein  (Rhinn, et al., 2012). In summary, α-
synuclein accumulations and aggregations are associated with PD pathology.  
Another protein that is strongly implicated in PD is leucine-rich repeat 
kinase 2 (LRRK2). Mutations in LRRK2 are the most common genetic cause of 
PD, with at least 20 mutations identified to date causing late onset, familial 
autosomal-dominant PD  (Orenstein, et al., 2013; Ferree, et al., 2012; Hsu, et al., 
2010; Saha, Liu-Yesucevitz, & Wolozin, 2014; Lesage, et al., 2006; Healy, et al., 
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2008). Most prevalent amino acid substitution is G2019S, located in the kinase 
domain of LRRK2. The other common amino acid substitution is R1441C in the 
Roc domain  (Zimprich, et al., 2004). However, the mechanisms of LRRK2, α-
synuclein and their implication for PD remain unclear (Plotegher & Civiero, 2012). 
Recent transcriptome and proteome studies have emphasized the diverse 
number of pathways regulated by LRRK2. In recent studies by the Dawson 
group, the regulation of translational functions by LRRK2 was highlighted, 
demonstrating that LRRK2 binds to and phosphorylates the ribosomal protein 
RPS15 (Martin, et al., 2014). This observation is concurrent with other studies 
demonstrating LRRK2’s roles as a negative mediator of miR mediated 
translational repression (Gehrke, Imai, Sokol, & Lu, 2010). A recent study 
employing systems biology to develop an in silico regulatory network of LRRK2 
also identifies RPS15 as a primary member of the LRRK2 regulatory network 
(Dusonchet, et al., 2014). Also, recent published proteomic study of LRRK2 by 
the Cookson laboratory identified Cyclin-G associated Kinase (GAK), which is the 
third strongest genetic risk factor for PD following synuclein and tau, as a strong 
binding protein (Beilina, et al., 2014; Dumitriu, et al., 2011; Pankratz, et al., 
2009). All these studies provide a strong implication for LRRK2’s role in 
translation. 3’UTR is a target region for RNA binding proteins and microRNAs 
(miRs), which lead to regulation of translation (Ambros, 2004; Bartel, 2004; 
Barrett, Fletcher, & Wilton, 2012; Pichon, et al., 2012). Thus, we are interested in 
examining α-synuclein with transcript isoforms of variant 3’ UTR and if LRRK2 
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has a role in regulating α-synuclein’s protein expression based on 3’UTR 
differences. This leads to our hypothesis that the expression and toxicity of α-
synuclein are regulated by LRRK2 post-transcriptionally through the interactions 
with the 3’UTR of α-synuclein.  
To investigate the biology of LRRK2 in α-synuclein protein expression, we 
examined both wild-type LRRK2 and mutant LRRK2 (G2019S and R1441C) in 
HEK-293 FT cells and primary cultures of rat hippocampal neurons. We 
observed that LRRK2 increases the protein expression level of α-synuclein. 
Mutation in LRRK2, G2019S, which has a gain-of-function in kinase activity 
(West, et al., 2005), leads to a greater increase in α-synuclein expression level 
compare to wild-type LRRK2. Comparing between the short and the long 3’UTR 
transcript isoform of α-synuclein, there is a higher level of α-synuclein protein 
expression from mRNAs with short 3’UTR compared to long 3’UTR in the 
presence of wild-type LRRK2 and G2019S. These data suggest differential 
effects of LRRK2 on α-synuclein depending on the type of 3’UTR.  
As the effects of LRRK2 depends on the type of 3’UTR, which is target 
region for miR in regulating translation, we investigated whether the regulation of 
α-synuclein expression by LRRK2 required the binding of miRs. Examining the 
sequence of the 3’UTR of α-synuclein with short 3’UTR transcript isoform, it has 
a binding site for miR-7, while that of long 3’UTR transcript isoform has binding 
sites for both miR-7 and miR-153 (Doxakis, 2010; Mouradian, 2012; Rhinn, et al., 
2012). We performed site-directed mutagenesis, mutating the binding sites for 
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either miR-7 and/or miR-153, where the miRs no longer can bind to α-synuclein 
3’UTR. Deletion of the miR-7 site abolished all effects of LRRK2 on expression of 
α-synuclein with short or long 3’UTR. In contrast, deleting the miR-153 site in α-
synuclein long 3’UTR resulted in a moderate decrement in the expression of the 
long 3’UTR α-synuclein. These results suggest that LRRK2 can modulate α-
synuclein expression via sites regulated by miRs, and in particular, miR-7 as the 
strongest mediator of LRRK2 actions. These data implicate a novel mechanism 
through which LRRK2 can regulate α-synuclein biology through miRs.  
 
Materials and Methods  
 
Constructs 
 Plasmids expressing C-terminal enhanced green fluorescent protein 
(EGFP)-tagged α-synuclein constructs with short or long 3’UTR were provided by 
Asa Abeliovich, Columbia University, New York  (Rhinn, et al., 2012).  
N-terminal 2X-Myc-tagged full-length human LRRK2 plasmids (wild-type, 
G2019S and R1441C) were kindly provided by Dr. Mark Cookson (National 
Institutes of Health, Bethesda, MD, USA) (Greggio, et al., 2006). 
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MicroRNA Mimics and Inhibitors  
MicroRNA-7 (5’ UGGAAGACUAGUGAUUUUGUUG 3’) and microRNA-
153 (5’ UUGCAUAGUCACAAAAGUGAUC 3’) mimics and inhibitors were order-
made through Life Technologies.  
 
Site-Directed Mutagenesis 
Site-directed mutagenesis was used to introduce point mutations at the 3’ 
untranslated region (UTR) of α-synuclein gene. The mutagenesis experiments 
were performed with the QuikChange II Site-Directed Mutagenesis Kit by Agilent 
Technologies according to the manufacturer’s protocol. The site-directed 
mutagenesis were targeted at the binding sites of miR7 and miR153 in the 3’ 
UTR of α-synuclein gene. MiR-7 site’s seed GUCUUCCA was mutated to 
GUCAACCA to and miR-153 site’s seed CUAUGCA was mutated to 
CAUUGCA, which abolished miR-7 and miR-153 binding to the corresponding 
sites (Doxakis, 2010)  
 
Cell Culture and Transient Transfection 
HEK-293 FT cells were maintained in media consisting of Dulbecco’s 
modified Eagle’s media (DMEM) 1X with L-glucose, L-glutamine and sodium 
pyruvate (Corning CellGro) supplemented with 10% fetal bovine serum (FBS) 
(Atlanta Biologicals), 1% nonessential amino aids and 1% penicillin and 
streptomycin (100 µg/ml) (Gibco by Life Technologies) and 1% L-glucose (2 mM) 
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(Gibco by Life Technologies) at 37oC, 5% CO2 atmosphere. Plasmid DNA was 
introduced into mammalian cells through transient transfection with 
Lipofectamine 2000 (Invitrogen, Life Technologies) according to the 
manufacturer’s instructions.  
 
Fluorescence Visualization and Quantification of EGFP-tagged α-synuclein 
 Fluorescent images of randomly selected fields of view were acquired 
using an upright Olympus IX50 equipped with epi-fluorescence optics and a 
digital camera (AxioCam MRm; Carl Zeiss Microscopy) with a fine objective to 
visualize EGFP-tagged α-synuclein expression. Quantification of the expression 
level of EGFP-tagged α-synuclein was performed by FLUOstar Optima by BMG 
Labtech. 
 
Primary Culture and Transfection 
 Primary cortical and hippocampal cultures were generated from 
embryonic day 18 (E18) progeny from pregnant Sprague-Dawley rats from 
Charles River Laboratories. Pregnant Sprague-Dawley rats were killed by 
inhalation of CO2. Embryos were then collected by cesarean section. Both males 
and females embryos were used. Cortices and hippocampi were dissected and 
collected separately in Calcium and Magnesium Free (CMF) solution containing 
10% Hank’s Balanced Salt Solution buffered with HEPES (HBSS) (Gibco), 42 nM 
sodium bicarbonate (Sigma), 1 mM Pyruvate (Sigma), 20 mM Hepes (Sigma) 
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and 3 mg/ml Bovine Serum Albumin (BSA), in Hyclone H2O (Invitrogen), pH 7.25-
7.30, and were digested with 0.25% trypsin for 9 minutes at 37oC, followed by 
trituration. Dissociated neurons were plated on glass coverslips pre-coated with 
poly-D lysine (100 µg/mL) and placed in plating media, which consists of 
neurobasal media (Invitrogen) supplied with 10% fetal bovine serum (FBS), 1% 
penicillin/streptomycin (100 µg/ml) and 0.5mM of L-Glutamine. After 2 to 3 hours 
of incubation, neurons were attached to cover glasses and the medium was 
replaced by feeding medium, consisting neurobasal medium (Invitrogen) with 2% 
B27 supplement, 1% penicillin/streptomycin (100 µg/ml) and 0.5mM of L-
Glutamine. Neurons were grown in feeding medium at 37oC and 5% CO2. 
Primary neurons were transiently transfected with plasmid DNA by transfection 
reagent Lipofectamine 2000 (Invitrogen, Life Technologies) at 5-6 days in vitro 
(DIV). DNA plasmids/lipofectamine solution was prepared with a ratio of 1 µg: 4 
µl and was incubated for 15 minutes at room temperature before adding to 
primary neurons. Neurons were incubated at 37oC, 5% CO2 for 20 minutes, 
which was then replaced by feeding media. At DIV 7 or 10 or 21, neurons were 
fixed in 4% paraformaldehyde for immunostaining and microscopy.  
 
Immunocytochemistry 
On DIV 7 or 10 or 21, the transfected cells were washed once with cold 1 
X PBS and were then fixed with 4% paraformaldehyde in 1 X PBS for 12 minutes 
at room temperature. The neurons were then washed 3 times with 1 X PBS for 5 
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minutes each. After the washes, the neurons were permeabilized with 0.1% triton 
X-100 in PBS for 15 minutes at room temperature. The neurons were washed 3 
times with 1x PBS for 5 minutes each and were then incubated in blocking 
solution of 5% BSA for 1 hour. After blocking, neurons were incubated with 1:400 
dilution of anti-c-myc (mouse, Sigma-Aldrich) or 1:1000 anti-MAP2 (mouse) 
antibodies for overnight in 4oC. On the next day, neurons were washed 3 times 
with 1x PBS for 5 minutes each at room temperature and were then incubated 
with 1:700 dilution of Alexa-594 donkey anti-mouse antibody (Jackson 
ImmunoResarch) in 1x PBS. The neurons then had a final wash step which 
consisted of 3 times with 1x PBS for 10 minutes each at room temperature. Then 
the coverslips are mounted on glass slides (Superfrost Plus Fisher Scientific) 
embedded in Prolong Gold Anti-fade DAPI gel mounting medium (Invitrogen).  
 
MitoTracker 
MitoTracker Red FM (ThermoFisher) is a far red-fluorescent dye with 
absorbance and emission of ~581/644 nm, which stains mitochondria in live cells 
and its accumulation is dependent upon membrane potential. To label 
mitochondria, MitoTracker probes stock solution of 1 mM final concentration was 
prepared with dimethylsulfoxide (DMSO) and was diluted to working 
concentration between 100-500 nM. Cells or neurons will then be incubate in the 
probes. After staining, the cells are washed in fresh, pre-warmed growth medium. 
Once mitochondria are labeled, the cells can be imaged live-cell or fixed. Most of 
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the MitoTracker probes are well-retained after fixation and permeabilization 
during subsequent immunocytochemistry.  
 
Neuronal Imaging. Olympus B60 Upright Microscope with a digital camera 
(AxioCam) (40X) and Zeiss Microscopy (20X, 40X, 63X) were used to visualize 
the expression, accumulation and localization of α-synuclein, mitochondria, and 
dendritic processes in primary culture neurons and the morphology of neurons 
under different transfection conditions . On average, 40 processes from 12 
different neurons in each group were analyzed. All images were processed by 
ImageJ and NeuronJ software and Adobe Photoshop CS2.  
 
Neurite Length Quantification 
 Neurite processes from neurons, stained with DAPI for nucleus, and 
positive for GFP-α-synuclein were stained with microtubule-associated protein 2 
(MAP2) by immunocytochemistry and were quantified using the PlugIn NeuronJ 
macros for ImageJ.  
 
Statistical Analysis 
All data were analyzed by Prism (GraphPad). One-way ANOVA and 
Tukey’s post hoc tests were ran to test and determine any statistically significant 
differences among datasets. All data were expressed as mean ± SEM and were 
graphed by using Microsoft Excel.  
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Results 
 
LRRK2 modulates the expression level of α-synuclein in a manner dependent on 
the length of the 3’ UTR (short or long) in HEK-293 FT cells 
A major hallmark of PD is the intracellular deposition of α-synuclein 
forming LBs (Alim, et al., 2002; Popescu, Lippa, Lee, & Trojanowski, 2004; 
Ferree, et al., 2012). We began our studies by investigating differential α-
synuclein protein expression in HEK-293 FT cells depending on the length of its 
3’UTR. 
Expressions of GFP-tagged alpha-synuclein in HEK-293 FT was verified 
by visualization with Olympus IX50 at 10x magnification (Figure 8).  
 
                                         
Figure 8. Representative images from HEK-293 FT cells expressing EGFP-α-
synuclein. EGFP-α-synuclein (bottom) in contrast to brightfield (top).  
 
 
Without LRRK2, there is no significant difference in expression levels 
between α-synuclein with short and long 3’ UTR (Figure 9).  
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Figure 9. Protein expression of α-synuclein mRNA transcript with short 3’UTR or 
with long 3’UTR in HEK-293 FT. In the absence of LRRK2, there is no statistical 
significant difference in α-synuclein protein expression between α-synuclein 
transcript isoforms with short 3’ UTR and the isoform with long 3’ UTR.  
 
 
On the other hand, when wild-type LRRK2 is present, bothα-synuclein with 
short 3’ UTR and long 3’ UTR have a significant increase in α-synuclein protein 
expression relative to cells without LRRK2, as measured by fluorescence level of 
the EGFP-tagged α-synuclein (Figure 10, p < 0.001). Comparing the amount of 
increase of α-synuclein by LRRK2 WT between α-synuclein with short and long 
3’ UTR, the 2-fold increase of α-synuclein protein of the short 3’ UTR isoform was 
significantly greater than that of long 3’ UTR isoform (Figure 10, p < 0.01).  
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Figure 10. LRRK2 modulates the expression level of α-synuclein in a manner 
dependent on the length of the 3’ UTR (short or long) in HEK-293 FT cells. In the 
presence of wild-type LRRK2, there is an increase in α-synuclein protein 
expression for both short and long 3’ UTR isoforms (p < 0.001). There is a 
greater increase for α-synuclein with short 3’ UTR than that with long 3’ UTR (p < 
0.01).  
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Mutations in LRRK2 (G2019S, R1441C) affect the regulation of the short and 
long 3’ UTR variants of α-Synuclein in HEK-293 FT.  
To test the effects of LRRK2 mutations in α-synuclein protein expression, 
we have used the PD-related mutants G2019S and R1441C. G2019S increases 
α-synuclein expression for both short and long 3’ UTR (Figure 11, p < 0.001). 
R1441C increases α-synuclein expression for short but not long 3’ UTR (Figure 
11, p < 0.01). There is a statistically significant higher expression level for α-
synuclein with short compare to long 3’UTR when HEK-293 FT cells were co-
transfected with either wild-type LRRK2, G2019S or R1441C LRRK2 mutants 
(Figure 11, p < 0.01). 
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Figure 11. Mutations in LRRK2 (G2019S, R1441C) affect the regulation of the 
short and long 3’ UTR variants of α-synuclein in HEK-293 FT. Further 
investigation of the effect of different mutant variants of LRRK2 (G2019S, 
R1441C) on α-synuclein protein expression shows that both G2019S and 
R1441C significantly increase the level of α-synuclein expression when it is co-
transfected with the short 3’ UTR isoform of α-synuclein transcript (p  < 0.001 
and p < 0.01 respectively). On the other hand, for the SNCA transcript with long 
3’UTR, G2019S, but not R1441C, significantly increases the level of α-synuclein 
protein level (p < 0.001). Comparing between the SNCA mRNA isoform with 
short versus long 3’ UTR, there is a greater α-synuclein protein expression with 
the short 3’ UTR SNCA transcript isoform when co-transfected with wild-type 
LRRK2, G2019S and R1441C (all p < 0.01 respectively).  
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LRRK2 increases α-synuclein accumulation along neuronal processes  
In addition to data in HEK-293 FT cells, our data showed that in cultured 
rat primary hippocampal neurons, in the presence of wild-type LRRK2 and 
G2019S, there is a higher level of α-synuclein protein expression (Figure 12, 13). 
In cases, with short 3’UTR compare to long 3’UTR co-expressing wild-type 
LRRK2, G2019S, or R1441C, neurons have a greater EGFP-α-synuclein 
expression and accumulation along the neuronal processes (Figure 13), 
suggesting a differential effect of LRRK2 on α-synuclein’s expression and 
accumulation depending on the length of its 3’UTR.  
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Figure 12. LRRK2 increases α-synuclein accumulation along neuronal processes 
in primary hippocampal neurons. Representative images from a primary 
hippocampal neuron expressing EGFP -α-synuclein. In conditions of α-synuclein 
with short 3’UTR co-expressed with wild-type LRRK2 and G2019S, but not 
R1441C, neurons demonstrate a broader distribution of α-synuclein along the 
neuronal processes. White Arrows = EGFP-α-synuclein accumulation in along 
processes.  
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Figure 13. Neurons transfected with α-synuclein with short 3’ UTR isoform higher 
α-synuclein protein expression levels compare to long 3’UTR in primary 
hippocampal neurons. For both short and long 3’ UTR isoform, there is a 
significant increase in α-synuclein protein expression in the presence of wild-type 
LRRK2 (p < 0.001 and p < 0.01 respectively) and similarly with mutant variant 
G2019S (both p < 0.001). There is also a greater protein expression for the short 
3’ UTR transcript isoform compare to the long 3’ UTR isoform without LRRK2 (p 
< 0.01), in the presence of wild-type LRRK2 (p < 0.001), G2019S (p < 0.001), 
and R1441C (p < 0.01). (Black bars - α-synuclein with short 3’ UTR; Clear bars - 
α-synuclein with long 3’ UTR). 
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LRRK2 regulates neuronal process length and complexity in primary 
neurons. Silencing or knockout of LRRK2 increases neurite length and 
branching; whereas, overexpression of PD-associated G2019S LRRK2 mutant 
induces neurite shortening  (Parisiadou, et al., 2009; Stafa, Trancikova, Webber, 
Glauser, West, & Moore, 2012; MacLeod, Dowman, Hammond, Leete, Inoue, & 
Abeliovich, 2006). Therefore, we investigated the effects of α-synuclein 
expression on G2019S LRRK2-induced neurite shortening.   
Rat primary hippocampal neurons were transfected at 5-6 days in-vitro 
(DIV) with and fixed at DIV21. Consistent with previous observations, we found 
that G2019S, but not R1441C, LRRK2 mutant induced neurite shortening and 
with a smaller but still significant effect of WT LRRK2 (Figure 14). As shown 
previously, α-synuclein with short 3’UTR has greater α-synuclein distribution 
along neuronal processes. In addition, α-synuclein with short 3’UTR has 
comparable neuronal processes length to α-synuclein with long 3’UTR (Figure 
15). By quantifying the neuronal length, we found that α-synuclein itself causes 
neurite shortening but does not have a synergistic or additional effect to LRRK2, 
suggesting that same pathway (Figure 16).  
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Figure 14. LRRK2 induces neurite shortening in primary hippocampal neurons. 
Wild-type LRRK2 and mutant G2019S, but not R1441C, induce neurite 
shortening in primary hippocampal neurons (p < 0.05 and p < 0.001 
respectively).  
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Figure 15. Representative images of MAP2 stained primary hippocampal 
neurons with α-Synuclein short or long 3’ UTR in the presence of wild-type 
LRRK2. α-Synuclein with short 3’UTR has greater α-synuclein distribution along 
neuronal processes but comparable neuronal processes length to α-synuclein 
with long 3’UTR.  
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) 
	  	  
93 
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Figure 16. α-Synuclein short or long 3’ UTR did not have an additive or 
synergistic effect on LRRK2-induced neurite shortening in primary hippocampal 
neurons. (A) α-Synuclein with short 3’UTR causes neurite shortening in the 
absence of LRRK2, in the presence of LRRK2 WT and G2019S (p < 0.05 
respectively). (B) α-Synuclein isoform with long 3’ UTR causes neurite shortening 
in the presence of LRRK2 WT and G2019S (p < 0.05 respectively). α-Synuclein 
short or long 3’ UTR did not have an additive or synergistic effect on LRRK2-
induced neurite shortening, suggesting they are regulated through the same 
pathway.  
	  	  
94 
 
LRRK2 effects on α-synuclein is miR dependent  
The 3’UTR is a target region for RNA binding proteins and miRs, and 
mediates regulation of translation. The ability of LRRK2 to regulate translation 
and miR biology led us to hypothesize that LRRK2 might regulate the expression 
and toxicity of α-synuclein through a mechanism involving miRs. Consistent with 
this hypothesis, we observed that LRRK2 increased α-synuclein expression and 
the degree of increase depended on the length of 3’UTR. Thus, we next 
investigated whether regulation of α-synuclein expression by LRRK2 required the 
binding of microRNAs. The short 3’UTR sequence of α-synuclein has a binding 
site for miR-7, while that of long 3’UTR has binding sites for both miR-7 and miR-
153 (Figure 17).  
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(A) 
 
     
 
(B) 
                     
 
                     
 
 
Figure 17. Illustrations of (A) the location of miRNAs binding sites on SNCA 
mRNA 3’UTR (B) the binding “seed” sequences within the SNCA mRNA 3’UTR 
(adapted from Doxakis, 2010). The α-synuclein transcript isoform with short 3’ 
UTR has a binding site for miR-7 at position 119-126; whereas, the isoform with 
long 3’ UTR has exactly the same sequence as the short isoform, thus has the 
same binding site for miR-7, plus an extended region, which includes a binding 
site for miR-153 at position 442-448.  
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We investigated the roles of these miRs. We showed that miR-7 mimic 
inhibits α-synuclein expression for both short and long 3’ UTR with an about 30% 
reduction in its protein expression for both isoforms (Figure 18A, p < 0.05 and 
Figure 18B, p < 0.05); whereas, miR-7 inhibitor enhances α-synuclein expression 
for both short and long 3’ UTR (Figure 19A, p < 0.05 and Figure 19B, p < 0.05). 
On the other hand, miR-153 mimic did not inhibit α-synuclein with long 3’UTR 
protein expression and miR-153 inhibitor has a mild effect in increasing α-
synuclein with long 3’UTR. Together, miR-7 and miR-153 inhibitors increase α-
synuclein protein expression of the long 3’UTR isoform (Figure 19B, p < 0.01). 
We then further investigated how these microRNAs interact with LRRK2 in 
regulating α-synuclein.  
 
 
 
 
 
 
 
 
 
 
	  	  
97 
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(B) 
          
 
Figure 18. MiR mimics inhibit α-synuclein protein expression in HEK-239 FT. (A) 
MiR-7 mimic inhibits α-synuclein protein expression for SNCA transcript isoform 
with short 3’UTR (p < 0.01). (B) MiR-7 mimic also inhibits α-synuclein protein 
expression for SNCA transcript isoform with long SNCA transcript isoform (p < 
0.01). Together miR-7 and miR-153 mimic significantly decrease α-synuclein 
expression (p < 0.05). However, MiR-153 itself has no significant effect. 
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(B)  
          
 
Figure 19. MiR inhibitors enhance α-synuclein protein expression in HEK-239 FT. 
(A) MiR-7 inhibitor enhances α-synuclein expression for the short 3’ UTR α-
synuclein mRNA transcript isoform (p < 0.01). (B) Also, miR-7 inhibitor enhances 
α-synuclein expression for the long 3’ UTR α-synuclein mRNA transcript isoform 
(p < 0.05). MiR-7 and miR-153 inhibitors together increase α-synuclein protein 
expression of the long 3’UTR isoform (p < 0.01). 
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To investigate the role of these miRs in LRRK2 regulation of α-synuclein, 
we performed site-directed mutagenesis, mutating the binding sites for either 
miR7 or miR153, where the miRs no longer can bind (Doxakis, 2010) (Figure 20).  
 
 
(A) 
                                 
 
(B) 
                                
 
 
Figure 20. Illustration of the site-directed mutagenesis of the binding sites for (A) 
miR-7 and (B) miR-153 (adapted from Doxakis, 2010).  
 
 
 We found that deletion of miR-7 site of the short 3’ UTR of α-synuclein 
transcript increase α-synuclein protein expression to a level that was significantly 
higher than non-mutated short 3’ UTR isoform (Figure 21, p < 0.001) and this 
level was comparable to non-mutated short 3’ UTR transcript isoform in the 
presence of LRRK2. Additionally, deletion of the miR-7 site abolished all effects 
of wild-type LRRK2 on expression of α-synuclein with short 3’UTR (Figure 21).  
 Similarly, when the binding site for miR-7 in the long 3’UTR of α-synuclein 
was mutated, protein expression of α-synuclein increased to a level that was 
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significantly higher compared to non-mutated long 3’ UTR isoform (Figure 22, p < 
0.001) and had no significant difference to non-mutated long 3’ UTR transcript 
isoform in the presence of LRRK2. On the other hand, when the binding site for 
miR-153 was eliminated, α-synuclein protein expression increased to a level that 
was significantly higher than the non-mutated version (Figure 22, p < 0.05) but at 
a level that was still statistically significant lower than non-mutated version in the 
presence of LRRK2 (Figure 22, p < 0.05).  
 In addition, when the binding site for miR-7 in the long 3’UTR of α-
synuclein was mutated, the effects of wild-type LRRK2 in increasing α-synuclein 
expression was eliminated (Figure 22).  
In contrast, when the binding site for miR153 in the 3’UTR of α-synuclein 
with long 3’UTR was mutated, it resulted in a moderate decrement in, but not 
complete elimination of, the increase in expression of α-synuclein by wild-type 
LRRK2 (Figure 22). Wild-type LRRK2 still led to a statistically significant increase 
of α-synuclein expression when miR-153 site was mutated and miR-7 site was 
still present (Figure 22, p < 0.05) though at a significantly reduced level compare 
to the increase in expression level of α-synuclein with long 3’UTR without site-
directed mutagenesis in the presence of wild-type LRRK2 (Figure 22, p < 0.001). 
This data suggested that LRRK2’s regulation of α-synuclein expression involves 
miRs.  
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Figure 21. The effects of wild-type LRRK2 on α-synuclein expression after site-
directed mutagenesis of miR-7 of SNCA mRNA with short 3’UTR in HEK-239 FT. 
When the binding site for miR-7 in the short 3’UTR of SNCA mRNA was mutated, 
the effects of wild-type LRRK2 in increasing α-synuclein expression was 
eliminated.  
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Figure 22. The effects of wild-type LRRK2 on α-synuclein expression after site-
directed mutagenesis of miR-7 of SNCA mRNA with long 3’UTR in HEK-293 FT. 
Deletion of miR-7 site abolished the effect of wild-type  LRRK2; whereas deletion 
of miR153 resulted in moderate decrement of wild-type LRRK2 effects, on 
protein expression of α-synuclein of SNCA mRNA with long 3’UTR. 
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Effect of LRRK2 on α-synuclein expression is dependent on LRRK2 kinase 
activity 
 
G2019S LRRK2 mutant is a gain-of-function mutation in the kinase 
domain. As G2019S has an enhanced increase in α-synuclein expression levels 
compare to the effect of increase by wild-type LRRK2 and R1441C, suggesting 
that the kinase domain of LRRK2 is important in this regulation. HEK-293 FT 
cells were treated with LRRK2 specific kinase inhibitor, LRRK2-In-1, and we 
found that the increase of α-synuclein expression by wild-type LRRK2 and 
G2019S were reduced (Figure 23), implicating the LRRK2 kinase activity is 
crucial in its effect in increasing α-synuclein expression.  
Additionally, we acknowledge that in recent years, LRRK2-In-1 has been 
shown to be less LRRK2 kinase specific than it was first demonstrated, leading to 
off-target effects. One of our future directions is to employ a different LRRK2 
kinase specific inhibitor other than LRRK2-In-1.  
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Figure 23: Effect of LRRK2 on α-synuclein expression is dependent on LRRK2 
kinase activity in HEK-293 FT. LRRK2-In-1 decreases the effects of LRRK2 
effects on expression of α-synuclein with short 3’UTR and long 3’UTR. 0.8µM of 
LRRK2-In-1 reduced the effects of LRRK2 on SNCA protein expression to no 
statistically significant difference between control and wild-type LRRK2 and 
effects of G2019S were significantly reduced from p < 0.001 to p < 0.05. Similarly 
for SNCA mRNA isoform with long 3’ UTR, LRRK2-In-1 decreases the effects of 
wild-type LRRK2 to non-significant level and reduced G2019S effect (from p < 
0.001 to p < 0.05).  
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Discussion 
.  
The regulatory mechanisms of LRRK2’s activity and toxicity remain poorly 
understood. LRRK2 has been shown to interact with many varied cellular 
proteins, including moesin, tubulin, MKK3, 6 and 7, JIP1, 3, and 4, arfGAP1, 
arhGEF7, endoA, cyclin-G associated kinase, rab5, rab7L1, 14-3-3,  (Hsu, et al., 
2010; Chan, Citro, Cordy, Shen, & Wolozin, 2011;  Hsu, Chan, & Wolozin, 2010; 
Gehrke, Imai, Sokol, & Lu, 2010; Beilina, et al., 2014; Imai, et al., 2008; Matta, et 
al., 2012; Häbig, et al., 2013; Kumar, et al., 2010; Nichols, et al., 2010; Shin, et 
al., 2008; Stafa, Trancikova, Webber, Glauser, West, & Moore, 2012; Ko, et al., 
2009; Sancho, Law, & Harvey, 2009; Dusonchet, et al., 2014), implicating a 
regulatory role in a wide variety of biological processes; such as, protein 
translation, cytoskeletal processes, vesicular dynamics, neurite extension, 
mitochondrial function, endoplasmic reticulum function and autophagy. 
Recent transcriptome and proteome studies have emphasized the diverse 
number of pathways regulated by LRRK2. In recent studies by the Dawson 
group, the regulation of translational functions by LRRK2 was accentuated, 
showing that LRRK2 binds to and phosphorylates the ribosomal protein RPS15 
(Martin, et al., 2014). This observation is concurrent with other studies 
demonstrating LRRK2’s roles as a negative mediator of miR-mediated 
translational repression (Gehrke, Imai, Sokol, & Lu, 2010). A recent study 
employing systems biology to develop an in silico regulatory network of LRRK2 
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to provide a comprehensive assessment of its cellular pathways also identifies 
RPS15 as a primary member of the LRRK2 regulatory network, where the two 
interact in a pathway that includes the ADP-ribose polymerase TNKS 
(Dusonchet, et al., 2014). Also, the Cookson’s group recently published a 
proteomic study of LRRK2, which identified Cyclin-G associated Kinase (GAK) as 
a strong binding protein to LRRK2 (Beilina, et al., 2014). GAK is the third 
strongest genetic risk factor for PD, following synuclein and tau  (Dumitriu, et al., 
2011; Pankratz, et al., 2009). All these studies provide a strong implication for 
LRRK2’s role in translation.   
 α-Synuclein aggregates in LB is one of the major hallmarks of PD (Alim, et 
al., 2002; Popescu, Lippa, Lee, & Trojanowski, 2004; Ferree, et al., 2012; 
Wakabayashi & Takahashi, 2000). However, the specific mechanisms regulating 
α-synuclein expression are poorly understood. Recent studies of α-synuclein 
have demonstrated various α-synuclein transcript isoforms exist (Rhinn, et al., 
2012). In our study, we found that α-synuclein with short or long 3’ UTR transcript 
isoform does not differ in the protein expression. However, in the presence of 
wild-type LRRK2, α-synuclein has an increase in its protein expression. While 
wild-type LRRK2 increases expression of α-synuclein for both short and long 
isoforms, transcript isoform with the short 3’ UTR has a greater increase in 
protein expression than that with the long 3’ UTR. When we analyze disease-
related LRRK2 mutants, G2019S and R1441C; G2019S, but not R1441C, lead to 
a further increase in α-synuclein expression compared to wild-type LRRK2 for 
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both the short and long transcript isoforms. Similarly with wild-type LRRK2, 
G2019S leads to a greater increase in α-synuclein protein expression for the 
short 3’UTR α-synuclein transcript isoform relative to the long 3’ UTR α-synuclein 
transcript isoform.   
 These results were confirmed in primary culture neurons. Our studies of 
hippocampal neurons show that there is a greater accumulation and broader 
distribution of α-synuclein expression along neuronal processes for the short 
isoform in the presence of LRRK2 WT and G2019S compare to the long 
transcript isoform, suggesting a differential effect of LRRK2 on α-synuclein’s 
expression and accumulation depending on the length of its mRNA 3’UTR. 
Previous studies have shown that LRRK2 regulates neuronal process 
length and complexity in primary neurons, in which silencing or knockout of 
LRRK2 increases neurite length and branching; whereas, overexpression of PD-
associated G2019S LRRK2 mutant induces neurite shortening (Parisiadou, et al., 
2009; Stafa, Trancikova, Webber, Glauser, West, & Moore, 2012;  (MacLeod, 
Dowman, Hammond, Leete, Inoue, & Abeliovich, 2006; Dusonchet, et al., 2014; 
Boon, Dusonchet, Trengrove, & Wolozin, 2014). In our studies, we are interested 
in looking at the effects of α-synuclein expression on G2019S LRRK2-induced 
neurite shortening. Consistent with previous studies, we found that G2019S 
LRRK2 mutant induced significant neurite shortening and wild-type LRRK2 had a 
smaller but yet significant effect on neurite shortening as well. Interestingly, we 
found that α-synuclein itself causes neurite shortening but does not have a 
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synergistic or additional effect to LRRK2. These results suggest that neurite 
shortening by LRRK2 and α-synuclein may be manipulated through the same 
pathway. 
 These interesting observations of LRRK2’s differential effect on α-
synuclein’s expression and accumulation depending on the length of its mRNA 
3’UTR lead us to further investigate the regulatory biology underlying these 
results. The 3’UTR of transcript is a target region for RNA binding proteins and 
for microRNAs, mediating translational regulation of proteins (Ambros, 2004; 
Bartel, 2004; Barrett, Fletcher, & Wilton, 2012; Pichon, et al., 2012). Together 
with LRRK2’s role in translation and its interaction with the microRNA biology, it 
lead to our hypothesis that LRRK2 regulates α-synuclein post-transcriptionally 
through a mechanism involving its 3’UTR and microRNAs.  
 Consistent with this hypothesis, our studies have demonstrated that the 
regulation of α-synuclein expression by LRRK2 requires the binding of 
microRNAs. The short 3’UTR of α-synuclein has a binding site for miR-7; 
whereas the long 3’UTR isoform has the same 3’UTR of the short isoform in 
addition of an extended region on the 3’ end, which has an additional miR 
binding site for miR-153, which is lacking in the short 3’UTR isoform. Concurrent 
with previous studies that miR-7 and miR-153 regulate α-synuclein protein 
expression (Doxakis, 2010; Mouradian, 2012), our results show that miR-7 mimic 
inhibits α-synuclein protein expression for both transcript isoforms. On the other 
hand, miR-7 inhibitor increases α-synuclein protein expression for both isoforms. 
	  	  
109 
When we studied the role of miR-153 in long 3’UTR transcript isoform of α-
synuclein, miR-153 mimic did not inhibit α-synuclein protein expression; whereas 
miR-153 inhibitor has a mild increase in α-synuclein protein expression.  
 To further investigate the role of these miRs in LRRK2 differential 
regulation of α-synuclein depending on the length of 3’UTR, we performed site-
directed mutagenesis. The binding sites of miR-7 or miR-153 on the 3’UTR of the 
transcripts were mutated, thus, the corresponding microRNAs could no longer 
bind. Interestingly, we found that the deletion of miR-7 site abolished all effects of 
LRRK2 on α-synuclein protein expression for both short and long 3’UTR 
transcript isoforms. In contrast, when miR-153 no longer bound to the long 
3’UTR, it lead to a moderate decrement in, but not complete abolishment of the 
effect of LRRK in increasing the expression of α-synuclein.  
These results suggest that LRRK2 and miR-7 regulate α-synuclein protein 
expression through the same pathway. In particular, miR-7 negatively regulates 
α-synuclein protein translation and LRRK2 negatively regulates miR-7 mediated 
translational regulation of α-synuclein, and thus relieving inhibition of α-synuclein 
by miR-7, which in turn leading to an increase in α-synuclein protein expression.  
On the other hand, miR-153 also negatively regulates α-synuclein protein 
translation; however, at a lesser extent compared to miR-7. Similar to miR-7, 
LRRK2 negatively regulates miR-153 mediated translational regulation of α-
synuclein, relieving inhibition of α-synuclein by miR-153, which in turn leading to 
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an increase in α-synuclein protein expression. However, α-synuclein protein 
translation is still negatively regulated by miR-7. Therefore, it resulted in an 
incomplete relief of α-synuclein protein expression from miRs inhibition. These 
results implicate that LRRK2’s regulation of α-synuclein expression involves the 
microRNA pathways, where miR-7 is the stronger mediator compared to miR-
153.  
 The observation that the LRRK2 mutant, G2019S, but not R1441C, leads 
to an enhanced increase in α-synuclein expression, it leads us to reason that the 
effect of LRRK2 on regulating α-synuclein protein expression is dependent on its 
kinase activity, as G2019S is a gain-of-function mutation locates in the kinase 
domain of LRRK2; whereas R1441C mutation locates in the ROC GTPase 
domain of LRRK2 leading to a reduced GTPase functioning. To investigate the 
importance of the kinase activity of LRRK2 in α-synuclein protein regulation, 
HEK-293 FT cells were treated with LRRK2 specific kinase inhibitor, LRRK2-In-1. 
Our results demonstrated that with LRRK2-In-1, the previous increase of α-
synuclein protein expression by LRRK2 WT and G2019S were significantly 
reduced. These data suggest that LRRK2 kinase activity is essential in its 
regulation of α-synuclein protein expression.  
 In summary, in the present study we discovered that LRRK2 post-
transcriptionally regulates α-synuclein protein expression and the regulation is 
dependent on the length of α-synuclein transcript’s 3’ UTR. In addition, our study 
identifies the kinase activity of LRRK2 regulates α-synuclein protein expression 
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via the microRNA pathway. The discovery of the interaction between LRRK2 and 
microRNA in regulating α-synuclein protein expression suggests a novel 
mechanism through which disease-linked mutations in LRRK2 might contribute to 
the pathophysiology of PD.  
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CHAPTER 4: OTHER STUDIES OF NEURODEGENERATIVE DISEASES 
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Introduction 
In addition to investigating LRRK2’s regulation of α-synuclein protein 
expression, I have also worked on other studies of neurodegenerative diseases 
by Wolozin’s group. 
 
ALS-Linked Mutations Enlarge TDP-43-Enriched Neuronal RNA Granules in the 
Dendritic Arbor 
(Adapted from Liu-Yesucevitz L, Lin AY, Ebata A, Boon JY, Teid W, Xu YF, 
Kobrin K, Murphy GJ, Petrucelli L, Wolozin B. ALS-linked mutations enlarge 
TDP-43-enriched neuronal RNA granules in the dendritic arbor. J Neurosci. 2014 
Mar 19;34(12):4167-74.) 
 
In the Journal of Neuroscience paper “ALS-Linked Mutations Enlarge 
TDP-43-Enriched Neuronal RNA Granules in the Dendritic Arbor”, Liu et al. were 
investigating whether disease-linked TDP-43 mutations may alter granule 
formation even in the absence of stress. Our laboratory has found that ALS-
linked mutations in TDP-43, A315T and Q343R, increase the size of TDP-43 
granules in the dendritic arbor of rat hippocampal neurons and reduce the 
granule density, movement, and mobility of such granules. As the issue of 
mobility is important when considering physiological responses to neural activity 
and as previous studies have shown that upon depolarization of neurons with 
KCl there is a strong translocation of TDP-43 to the dendritic arbor, we were 
interested in investigating if the slower mobility of TDP-43 might affect its 
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response to neuronal depolarization. 
 To test this, in particular, I cultured rat hippocampal neurons for 
transfection with wild-type or mutant (A315T or Q343R) TDP-43. Cells were later 
stimulated with KCl (performed by A. Lin). We found that mutant TDP-43 exhibits 
reduced dendritic localization upon neuronal depolarization. When rat 
hippocampal neurons were depolarized with KCl, TDP-43 granules were 
stimulated to migrate into dendrites. However, A315T and Q343R TDP-43 
granules have a shorter distance migration and they migrate into fewer dendrites 
compare to wild-type TDP-43. Specifically, we found a 70% decrease of dendritic 
translocation of mutant TDP-43 in response to KCl depolarization. We found that 
mutation-induced increases in the propensity of TDP-43 to aggregate leads to 
neuronal granules moving at a slower rate, implicating slower response of TDP-
43 to changes in neuronal activity in the dendritic arbor. These results suggest 
that disease mutant of TDP-43 may interfere with its normal dendritic function 
with its reduced mobility and it may modify its biology in the neuronal arbor 
before overt degeneration, suggesting an early pathophysiological mechanism in 
dendrites and synapses before the course of the disease.  
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Figure 24. Localization of TDP-43 after KCl-induced depolarization of 
hippocampal neurons. Cultured rat hippocampal neurons were transfected with 
TDP-43::GFP (WT, A315T, or Q343R). Twenty-four hours after transfection, the 
neurons were treated with TTX (1 µM) for 1 h, pulsed with 90 mM KCl 4 X 3 min, 
allowed to incubate for 6 h, and then GFP was imaged directly. A–C, 
Representative images of TDP-43::GFP (WT, A315T, and Q343R) in the 
hippocampal neurons. D–F, Tracings of TDP-43 present in the processes from 
images from A–C. G, Quantification of distance traveled by WT, A315T, and 
Q343R TDP-43. H, Quantification of the number of neurites per neuron exhibiting 
evidence of TDP-43 (WT, A315T, and Q343R) puncta in the soma or dendritic 
arbor. Scale bar, 10 µm (Adapted from Figure 4, Liu-Yesucevitz, et al., 2014). 
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A Parkinson’s disease gene regulatory network identifies the signaling protein 
RGS2 as a modulator of LRRK2 activity and neuronal toxicity  
(Adapted from Dusonchet J, Li H, Guillily M, Liu M, Stafa K, Derada Troletti C, 
Boon JY, Saha S, Glauser L, Mamais A, Citro A, Youmans KL, Liu-Yesucevitz L, 
Shcneider BL, Aebischer P, Yue Z, Bandopadhyay R, Glicksman MA, Moore DJ, 
Collins JJ, Wolozin B. A Parkinson’s disease gene regulatory network identifies 
the signaling protein RG2 as a modulator of LRRK2 activity and neuronal toxicity. 
Hum Mol Genet. 2014 Sep 15;23(18):4887-905.) 
 
In the Human Molecular Genetics paper, “A Parkinson’s disease gene 
regulatory network identifies the signaling protein RGS2 as a modulator of 
LRRK2 activity and neuronal toxicity”, Dusonchet et al. reverse-engineer a 
LRRK2-centered gene regulatory network through systems biology to human PD 
brain and blood transcriptomes in order to identify the signaling proteins that 
regulate LRRK2 function and toxicity for the development of effective therapeutic 
strategies as currently, the signaling mechanisms that regulate LRRK2 and the 
pathogenic effects of familial mutations remain unknown.  
Dusonchet et al. identified RGS2, a signaling gene encoding for a 
GTPase, as a key regulatory hub connecting the genes associated with familiar 
PD; such as DJ-1 and PINK1, with LRRK2 in the network and its expression 
levels are reduced in the striata of LRRK2 and sporadic PD patients. In order to 
study RGS2 regulation of LRRK2, we investigated how it regulates the GTPase 
and kinase activities of LRRK2.  
In particular, I worked on the investigation of RGS2 on the kinase activity 
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of LRRK2. Specifically, after we found that RGS2 inhibits LRRK2 kinase activity, I 
verified the inhibition of LRRK2 kinase activity by examining LRRK2 
autophosphorylation sites. In order to address this, HEK-293 cells co-expressing 
V5-LRRK2 and RGS2 were lysed and probed with antibodies against LRRK2 
with anti-V5, or phosphospecific LRRK2 antibodies. Phosphorylation of LRRK2 at 
Ser910 was reduced in the presence of RGS2. However, phosphorylation at 
Ser935 was not affected by RGS2. Together with other findings in this paper, we 
identified RGS2 as a novel interacting partner of LRRK2 in vivo, where RGS2 
regulates both the GTPase and kinase activities of LRRK2 and it regulates 
LRRK2’s function in modulating length of neuronal processes. In summary, our 
results suggest RGS2 as a potential target for interfering with neurodegeneration 
in PD patients with LRRK2 mutations.  
 
Figure 25. RGS2 regulates the GTPase and kinase activities of LRRK2. HEK 
cells were transfected with V5-LRRK2 (WT) + RGS2. Lysates were collected and 
probed for total LRRK2 (anti-V5, left panel), RGS2, actin, phospho-Ser910-
LRRK2 (middle panel) and phospho-Ser935-LRRK2 (right panel). Only phospho-
Ser910-LRRK2 was reduced by co-expression with RGS2. (Adapted from Figure 
5E, Dusonchet, et al., 2014) 
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HDAC6 and LRRK2 Interact to Regulate Autophagy and Dopaminergic Neuronal 
Survival  
(Adapted from Wolozin B, Trengrove C, Boon JY, Li H, Guillily MD, Dusonchet J, 
Gowda V, Chan D, Citro A, Saha S, Hoss A, Zaarur N, Mamais A, 
Bandopadhyay R. HDAC6 and LRRK2 Interact to Regulate Autophagy and 
Dopaminergic Neuronal Survival. PlosOne (Submitted)) 
 
In our PLoS One paper titled HDAC6 and LRRK2 Interact to Regulate 
Autophagy and Dopaminergic Neuronal Survival, Trengrove et al. applied 
systems biology tool to identify potential mechanism regulating LRRK2’s 
functions on tubulin acetylation and autophagy. We found that the histone 
deacetylase 6, HDAC6, which regulates both tubulin acetylation and autophagy, 
was one of the genes identified in the network as sharing the most number of 
links with LRRK2, suggesting a strong physiological link between LRRK2 and 
HDAC6.  
To address this question, we tested whether LRRK2 and HDAC6 interact 
and form a complex together. Trengrove et al. have found that endogenous 
LRRK2 binds to HDAC6 in human brain samples. Specifically, I investigated PD-
related mutant variants of LRRK2 and how they affect the ability of LRRK2 to 
bind with HDAC6. V5-tagged wild-type LRRK2, G2019S and R1441C were co-
transfected with Flag-tagged HDAC6 into HEK-293 cells. We investigated the 
binding of LRRK2 and HDAC6 through immunoprecipitation of V5-LRRK2. We 
found that each LRRK2 construct was readily co-immunoprecipitated with 
HDAC6 and there were no consistent differences due to mutations.  
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Together, these results show that LRRK2 binds to HDAC6 both in vivo 
and in vitro. Trengrove et al. further investigated the interaction between LRRK2 
and HDAC6 and found that HDAC6 is phosphorylated by LRRK2 and the binding 
of LRRK2 with HDAC6 stimulates tubulin deacetylation and regulates 
autolysosomal function. Specifically, upregulation of HDAC6 is able to rescue 
neurite retraction induced by G2019S. Together, these results show that HDAC6 
has an important role in regulating LRRK2’s functions and suggesting HDAC6 to 
be a potential therapeutic target. 
 
 
Figure 26: Association of LRRK2 with HDAC6. Co-IPs from HEK-293T cells 
transfected with V5-LRRK2 and FLAG-HDAC6 show HDAC6 binding mutant 
LRRK2 as well as WT LRRK2 (Adapted from Figure 2B, Trengrove, et al., 
submitted 2015) 
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Development of a novel TDP-43 granule inhibitor: A putative mode of action 
through the reduction of TDP-43 phosphorylation 
(Adapted from Ebata A, Lusic H, Boyd JD, Boon JY, Ash P, Li H, Collins JJ, 
Hodgetts K, Glicksman MA, Wolozin B. Development of a novel TDP-43 granule 
inhibitor: A putative mode of action through the reduction of TDP-43 
phosphorylation. Society for Neuroscience Meeting, Chicago, October 2015. ) 
 
 In addition, I have also worked on the TDP-43 project, which is the main 
thesis project of Atsushi Ebata in the laboratory. In particular, we are 
investigating the novel phosphorylation sites T103/S104 of TDP-43 in regulating 
TDP-43 protein’s granule formation and also if Compound 8 has an effect in this 
regulation. This work contributes to Ebata A’s thesis work and has been 
presented as a poster at the Society for Neuroscience meeting, Chicago, 2015.  
 TDP-43 is an RNA binding protein, which accumulates in the cytoplasm of 
brain and spinal cord of amyotrophic lateral sclerosis (ALS) and frontotemporal 
lobar degeneration (FTLD) patients. Mutations in TARDBP, the TDP-43-encoding 
gene, increase formation of intracellular TDP-43 granules in both familiar and 
sporadic ALS and FTLD patients. In the poster “Development of a novel TDP-43 
granule inhibitor: A putative mode of action through the reduction of TDP-43 
phosphorylation”, Ebata et al. investigated the role of TDP-43 in the 
pathogenesis of ALS and FTLD and potential therapeutic targets.  
 Ebata et al. screened a chemical library of 75,000 compounds and identified 
Compound 8 as a candidate compound. To help address the effect and mode of 
actions of compound 8, Ebata et al. looked at various phosphorylation sites of 
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TDP-43. Ebata et al. have discovered new TDP-43 phosphorylation sites at 
T103/S104 and to validate these novel TDP-43 phosphorylation sites and to 
investigate the effect of phosphorylation on TDP-43 granule function, I have 
generated phospho-mimetics and phospho-null mutants through site-directed 
mutagenesis. 
 In particular, I mutagenized the T103/S104 sites in the sequence 
KRAVQKTSDLIVLG for double mutations as T103D/S104D and T103A/S104A 
for phospho-mimetic and phospho-null double mutants. These plasmids were 
then transiently transfected into SH-SY5Y cells. Ebata et al.’s results show that 
while wild-type and phospho-null (T103A/S104A) TDP-43 localized to the 
nucleus in a diffuse pattern 12% of cells that expressed phosho-mimetic TDP-43 
(T103D/S104D) formed high-intensity aggregates in nucleus or cytoplasm 
spontaneously.  
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Figure 27. The effect of phospho-mimetic and null mutations at S103/T104 of 
TDP-43 on TDP-43 granule formation. Association of LRRK2 with HDAC6. SH-
SY5Y cells were transiently transfected with the plasmid constructs harboring 
GFP-tagged phospho- mimetic or -null form of TDP-43(S103/T104), and they 
were treated with 10 µM sodium arsenite for 24 hours. The nuclei were 
counterstained with DAPI. (A) The representative images of GFP expression 
pattern are shown. (B & C) The quantitative analysis was performed by 
calculating the fraction of GFP- positive cells with intracellular TDP-43-EGFP 
granules. TS, wild type, AA, phospho-null, and DD, phospho-mimetic. The data 
was statistically analyzed with the one-way ANOVA with Tukey’s test (B), or two-
way ANOVA (C). **, P < 0.01 & ****, P < 0.0001 (Adapted from Figure 13, Ebata, 
2015) 
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Table 3: The effect of phospho-mimetic and null mutations at T103/S104 of TDP-
43 on its granule formation (Adapted from Table 12, Ebata, 2015). 
 
 
 
Table 4: Statistical analysis of the effect of arsenite and T103/S104 phenotype on 
TDP-43 granule formation (Adapted from Table 13, Ebata, 2015). 
 
 
 Ebata et al. further tested the effect of the TDP-43 granule inhibitor, 
Compound 8j, in reducing TDP-43 granules in SH-SY5Y cells expressing the 
phosho-mimetic (T103D/S104D) mutant and found that Compound 8 reduces 
granule formations when the cells were treated with arsenite. Arsenite treatment 
itself increased granule formations and Compound 8 reduced the increase of 
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granules by arsenite. However, it did not reduce granule formations under basal 
conditions. These results lead to Ebata et al. to draw the conclusion that 
phosphorylation of these newly identified phosphorylation sites, T103/S104, is 
sufficient to induce TDP-43 granules formation; however, it may not regulate 
granule formation under stressed conditions.  
 
 
 
 
Figure 28.The effect of C8j on the arsenite-induced TDP-43 (T103/S104) 
granules in human neuroblastoma cells. SH-SY5Y cells were transiently 
transfected with wild-type (A), phospho-null (B), or phospho-mimetic (C) EGFP-
TDP-43 (T103/S104) expression plasmids. The cells were co-treated with sodium 
arsenite and C8j. Fraction of cells with small nuclear puncta and intracellular 
aggregate was plotted and Chi-square analysis was performed between no-
arsenite and arsenite treated groups, and between DMSO and C8j treated 
groups for each genetic background. * P < 0.05, ** P < 0.01, **** P < 0.0001 
(Adapted from Figure 14, Ebata, 2015) 
 
 
 
 
 
 
	  	  
125 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 5: DISCUSSION  
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LRRK2 regulates α-synuclein expression post-transcriptionally via micro-
RNA 
 
Hypothesis 
LRRK2 regulates α-synuclein expression post-transcriptionally via micro-RNA.  
 
Specific Aims 
• Aim 1: To determine whether LRRK2 modulates α-synuclein protein 
expression in a manner dependent on the length of its 3’ UTR. 
• Aim 2: To determine whether the differential regulation of α-synuclein 
expression by LRRK2 requires the bindings of microRNAs. 
• Aim 3: To determine whether LRRK2 kinase function is essential to its 
regulation of α-synuclein expression. 
 
Aim 1: To determine whether LRRK2 modulates α-synuclein protein expression 
in a manner dependent on the length of its 3’ UTR. 
 
Our results show that LRRK2 modulates the expression level of α-
synuclein in a manner dependent on the length of the 3’ UTR in HEK-293 FT 
cells. We have found that in the presence of wild-type LRRK2, both α-synuclein 
with short 3’ UTR and long 3’ UTR have a significant increase in α-synuclein 
protein expression in relative to without. In addition, there was a greater increase 
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of α-synuclein protein expression with short 3’ UTR compare to that of long 3’ 
UTR in the presence of LRRK2. As a negative control, LRRK2 did not increase 
expression levels of EGFP or α-synuclein without 3’UTR (Figure 29).  
 
 
 
 
(A)                                                              (B) 
               
 
Figure 29. LRRK2 does not increase expression levels of (A) EGFP or (B) α-
synuclein without 3’UTR.   
 
 
 
 
 
	  	  
128 
We have also found that mutations in LRRK2 (G2019S, R1441C) affect 
the regulation of the short and long 3’ UTR variants of α-synuclein in HEK-293 
FT. Our results showed that disease mutant G2019S increases α-synuclein 
expression for both short and long 3’ UTR transcript isoform of SNCA. On the 
other hand, R1441C increases α-synuclein expression for short but not long 3’ 
UTR isoform. Furthermore, when we compare comparing between the short and 
the long isoforms, there is a higher protein expression level for the short isoform 
in the presence of either wild-type LRRK2, G2019S or R1441C. 
In addition to data in HEK-293 FT cells, LRRK2 increases α-synuclein 
accumulation in primary neurons along neuronal processes. In particular, in rat 
primary culture hippocampal neurons, there is a distinct difference in the 
accumulation and localization of α-synuclein in neurons for the two isoforms in 
the presence of either wild-type LRRK2, G2019S, or R1441C, where neurons 
with the short isoform have a greater EGFP-α-synuclein expression and 
accumulation along the neuronal processes compared to the long isoform when 
visualized in rat primary cultured hippocampal neurons. This is in concordance 
with our HEK-293 FT studies results and these results suggest a differential 
effect of LRRK2 on expression and accumulation of α-synuclein depending on 
the length of its 3’UTR. 
Previous studies have shown that LRRK2 regulates neuronal process 
length and complexity in primary neurons and induces neurite shortening. This 
led us to our interest in studying the effects of α-synuclein expression on G2019S 
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LRRK2-induced neurite shortening. Consistent with previous observations, we 
found that disease mutant G2019S induced neurite shortening and with a smaller 
but still significant effect of wild-type LRRK2. In addition, we found that α-
synuclein itself causes neurite shortening; however it does not have a synergistic 
or additional effect to the effect of LRRK2. These results suggest that α-synuclein 
and LRRK2 may regulate neurite length and cause neurite shortening through 
the same biological pathway. However, there is no difference in the average 
number of neurites per neuron between α-synuclein with short 3’UTR or long 
3’UTR isoforms, with or without the presence of wild-type LRRK2, G2019S or 
R1441C (Figure 30). 
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Figure 30. Average number of neurites per neuron with short 3’UTR or long 
3’UTR. There is no statistically significant difference in the average number of 
neurites per neuron between α-synuclein with short 3’UTR or long 3’UTR with or 
without wild-type LRRK2, G2019S or R1441C. 
 
 
Furthermore, we were interested to study if α-synuclein were co-localized 
and travelled with mitochondria along neuronal processes as some studies 
suggested previously (Rhinn, et al., 2012). Our results showed that α-synuclein 
does not co-localize with mitochondria and travelled along processes separately 
(Figure 31).  
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(A) 
 
(B) 
               
Figure 31. α-Synuclein does not co-localize with mitochondria. (A) Rat 
hippocampal neurons expressing EGFP-α-synuclein stained with Mitotracker 
Red. (B) High magnification of merged color channels images.  
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In summary for the results of Aim 1, wild-type LRRK2 and mutant LRRK2 
(G2019S and R1441C) modulate α-synuclein translation, where it increases the 
protein expressions of α-synuclein in both HEK-293 FT cells and primary culture 
neurons. In particular, α-synuclein transcript isoform with short 3’UTR is 
associated with a higher protein expression level relative to the isoform with the 
long 3’UTR in the presence of LRRK2. These data suggest differential effects of 
LRRK2 on α-synuclein depending on the type of its 3’UTR.  
 
Aim 2: To determine whether the differential regulation of α-synuclein expression 
by LRRK2 requires the bindings of microRNAs. 
Our results show that miRs regulate α-synuclein protein expression. 
Consistent with our hypothesis, we observed that LRRK2 increased α-synuclein 
expression and the degree of increase depends on the length of 3’UTR as shown 
in aim 1. This led to our interest to determine if the mechanism of this effect of 
LRRK2 involves miRs. Henceforth, we next investigated whether regulation of α-
synuclein expression by LRRK2 requires the binding of miRs.  
Our results show that miR-7 mimic inhibits α-synuclein expression for both 
short and long 3’ UTR. On the other hand, when using a microRNA inhibitor, we 
found that miR-7 inhibitor enhances α-synuclein expression for both short and 
long 3’ UTR. MiR-153 mimic did not inhibit α-synuclein with long 3’UTR protein 
expression. Additionally, we found that miR-153 inhibitor has a mild effect in 
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increasing α-synuclein with long 3’UTR. Together, miR-7 and miR-153 inhibitors 
increase α-synuclein protein expression of the long 3’UTR isoform. 
Furthermore, we found that the effects of LRRK2 on α-synuclein 
expression is miR dependent. We found that mutation of the miR-7 site abolished 
the effects of wild-type LRRK2 on expression of α-synuclein with short 3’UTR 
transcript isoform. Similarly, when the binding site for miR-7 in the long 3’UTR of 
SNCA transcript isoform was mutated, the effect of wild-type LRRK2 in 
increasing α-synuclein expression was eliminated. In contrast, when we mutated 
the binding site for miR-153 in the 3’ UTR of SNCA transcript isoform with long 3’ 
UTR so that miR-153 can no longer bind, our results showed a moderate 
decrement in, but not complete elimination of the increase in expression of α-
synuclein by wild-type LRRK2. In addition, wild-type LRRK2 retains its ability to 
increase α-synuclein protein expression of SNCA with long 3’UTR transcript 
isoform when miR-153 site was mutated while miR-7 site was still present. Yet 
this increase was at a significantly reduced level compared to the increase in α-
synuclein protein expression level for long 3’ UTR SNCA isoform without site-
directed mutagenesis in the present of wild-type LRRK2.  
In summary, these data suggested that miR pathways interact with LRRK2 
regulation of α-synuclein expression. In particular, these results suggested that 
LRRK2 modulates α-synuclein expression via sites regulated by miRs, and in 
particular, miR-7 as the strongest mediator of LRRK2 actions. As an increase in 
α-synuclein protein deposition is associated with PD, a reduction in the increase 
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of α-synuclein by LRRK2 through microRNA pathway provides insight into 
potential therapeutic targets.  
 
Aim 3: To determine whether LRRK2 kinase function is essential to its regulation 
of α-synuclein expression. 
Our results show that G2019S induces greater α-synuclein protein 
expression compare to wild-type LRRK2 in both HEK-293 FT cells and rat 
primary hippocampal neurons. G2019S is the most prevalent disease-related 
mutant variant of LRRK2, leading to late onset autosomal dominant familial PD 
(Mata, et al., 2006). It is a gain-of-function mutation with an enhanced kinase 
activity without affecting the GTPase activity of LRRK2 (West, et al., 2005). 
These results suggest that the kinase function of LRRK2 is important in its 
regulation of α-synuclein protein expression. 
We found that the effects of LRRK2 on α-synuclein expression are 
dependent on LRRK2 kinase activity. As G2019S is associated with an enhanced 
increase in α-synuclein protein expression level compared to the effect of 
increase by wild-type LRRK2 and R1441C, it supports the importance of 
LRRK2’s kinase function. Thus, we were interested in investigating if the effect of 
LRRK2 on α-synuclein expression is dependent on LRRK2’s kinase activity. To 
address this question, we first used a Kinase Dead plasmid of LRRK2 in HEK-
293 FT cells. However, we did not see any effect of kinase dead LRRK2 on α-
synuclein protein expression compared to in the absence of LRRK2. To verify the 
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results, we ran western blots and probe for LRRK2 and the amount of kinase 
dead LRRK2 was at extremely low expression level. Researching previous work 
done with this particular plasmid, another investigator has also found that this 
particular plasmid has very low expression level to be useful to prove the 
hypothesis. Hence, we turned to other agents in studying whether the effects of 
LRRK2 on α-synuclein protein expression are dependent on its kinase activity. 
The LRRK2 specific kinase inhibitor, LRRK2-In-1, was used to selectively inhibit 
LRRK2 kinase activity. HEK-293 FT cells co-expressing LRRK2 and α-synuclein 
were treated with LRRK2-In-1 and our results show that the increase of α-
synuclein protein expression by wild-type LRRK2 and G2019S were reduced. In 
summary, these data implicate LRRK2 kinase activity as important in its effect on 
increasing α-synuclein protein expression.  
 
Relieves from MiR inhibition of α-synuclein protein expression by LRRK2 
 
MiRs inhibits α-synuclein protein expression 
 As our results showed, α-synuclein protein expression is regulated and 
inhibited by miRs, in particular miR-7 as the stronger mediator relative to miR-
153. In short, mimics of the respective miR complementary to mRNA binding 
sites inhibit α-synuclein protein expression; whereas the respective miR inhibitors 
enhance α-synuclein protein expression. In addition, site-directed mutagenesis 
eliminating miRs binding sites have demonstrated that without the binding of 
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miRs, α-synuclein protein expression increases. All these results indicate that α-
synuclein protein expression is inhibited by miRs and when miRs are inhibited, α-
synuclein is relieved from miRs’ inhibition leading to an increase in its protein 
expression.  
 
LRRK2 reduces miRs inhibition of α-synuclein protein expression 
 Our results show that LRRK2 increases α-synuclein protein expression. In 
addition, when miRs binding sites are eliminated, LRRK2 lost its effect in 
increasing α-synuclein protein expression. These results suggest that LRRK2 
and miR-7 regulate α-synuclein protein expression through the same pathway.  
 We interpret our results where miR-7 inhibits α-synuclein protein 
expression and this inhibition is eliminated when LRRK2 is present. This 
suggests that LRRK2 negatively regulates miR-7 mediated translational 
regulation of α-synuclein. This in turn leads to a relief of inhibition of α-synuclein 
by miR-7, resulting in an increase in α-synuclein protein expression.  
 These results indicate that the increase of α-synuclein protein expression 
by LRRK2 is by alleviating the inhibition of α-synuclein protein expression by 
miRs. 
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LRRK2 alleviates inhibition of α-synuclein protein expression by miRs via 
interaction with the RISC  
Our results are consistent with previous studies, which have shown that 
LRRK2 interacts with the miRs pathway to regulate protein synthesis, where it 
associates with the RISC and negatively regulates miRs (Gehrke, Imai, Sokol, & 
Lu, 2010).  
Our results can be interpreted via the hypothetical model of LRRK2 
regulation of miR-mediated translational regulation. Studies have shown that 
LRRK2 binds to and phosphorylates 4E-BP. Phosphorylated 4E-BP will then 
dissociate from eIF4E and the free phosphorylated 4E-BP can bind to eIF2c and 
Argonaute, which are proteins essential to the RISC function (Imai, et al., 2008; 
Doral & Hébert SS, 2012). This association of phosphorylated 4E-BP and 
eIF2c/Argonaute lead to an inhibition of the RISC complex-mediated mRNA 
translational repression via miRs binding to complementary sequences in the 3’ 
UTR of the target mRNAs. Therefore, by inhibiting the miRs/RISC inhibition of α-
synuclein protein expression, LRRK2 increases α-synuclein protein expression.  
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Implications for α-synuclein pathology and PD 
 
One of the major hallmarks of PD is the deposition of intracellular Lewy 
body inclusions, formed by accumulation and aggregation of α-synuclein protein. 
In addition, studies have shown that increased SNCA gene dosage may lead to 
earlier disease onset and severity in wild-type α-synuclein mouse models and 
this was in concordance with the identification of families with duplications or 
triplications of the wild-type α-synuclein gene (Singleton, et al., 2003; Nishioka, et 
al., 2006). In general, an upregulation of α-synuclein protein level is associated 
with PD.  
In addition, G2019S, PD-associated mutant variant of LRRK2, has an 
increased kinase activity and can further stimulate the interaction between 
phosphorylated 4E-BP with Argonaute, leading to an upregulation of protein 
translation which may in turn result in various consequences, such as protein 
aggregation, cell stress, and ultimately, cell death (Doral & Hébert SS, 2012).  
In summary, an upregulation of α-synuclein protein level is correlated with 
has PD and LRRK2 has been shown to increase α-synuclein protein expression 
via miRs. Therefore, through understanding the mechanisms and key factors and 
proteins involve in α-synuclein protein translation, may lead to insights in 
reducing its protein level ad potentially ameliorate symptoms of PD or halt 
diseases progression. 
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Summary 
 
A mRNA transcript can either undergo translation to protein or it can be 
silenced by miRs with the RISC. Our results are consistent with and support our 
hypothesis in which LRRK2 regulates α-synuclein expression post-
transcriptionally, at least in part, via a miR pathway. Our studies have 
demonstrated that LRRK2 can regulate α-synuclein protein expression via miRs, 
which is in concordance of previous studies showing that LRRK2 negatively 
mediates microRNA-mediated translation repression (Gehrke, Imai, Sokol, & Lu, 
2010). In the presence of LRRK2, the effect of miR-7 in silencing α-synuclein 
protein expression is inhibited. This relieves of inhibition of α-synuclein protein 
expression from miR-7 in turn leads to an increase in α-synuclein protein 
expression. Our results show that miR-7 is the stronger mediator for LRRK2 
regulation of α-synuclein protein expression when compared to miR-153.  
For both the short and long isoforms, there is a binding site for miR-7, 
mediating α-synuclein protein expression. However, in addition to miR-7, the 
SNCA transcript isoform with long 3’UTR has a binding site for miR-153 as well. 
Therefore, we interpret the differences we observe in protein expression of α-
synuclein between SNCA transcript isoform with short and long 3’ UTR is due to 
the additional miR-153 binding site, which provides a pathway to miRNA-
mediated translation repression, leading the long 3’UTR transcript isoform to a 
greater inhibition by miR/RISC and henceforth resulting in a smaller increase in 
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α-synuclein protein expression by LRRK2 compared to the transcript isoform with 
short 3’UTR.  
Through further investigation in the mechanism of how LRRK2 and miR 
interact to regulate α-synuclein protein expression, we found that LRRK2 kinase 
function is essential in this regulation. With a LRRK2 specific kinase inhibitor, the 
increase in α-synuclein protein expression by LRRK2 was inhibited. From these 
results, we can interpret that when the kinase function of LRRK2 is inhibited, 
LRRK2 loses its effect in negatively mediating miR-mediated translational 
repression, leading to the reduction of LRRK2 effect on increasing protein 
expression of α-synuclein.  
In summary, our studies found that LRRK2 regulates α-synuclein protein 
expression post-transcriptionally and this regulation is dependent on the length of 
SNCA mRNA transcript’s 3’ UTR (Figure 32). Our results have also identified that 
miR-7 is the stronger mediator than miR-153 in regulating α-synuclein protein 
expression. Moreover, we have found that the kinase activity of LRRK2 is 
essential in regulating α-synuclein protein expression via the miRs. The 
discovery of interaction between LRRK2 and miRs in regulating α-synuclein 
protein expression implicates novel mechanisms through which disease-linked 
mutations in LRRK2 may contribute to the pathophysiology of PD and these 
results suggest microRNAs as potential therapeutic targets for interfering with α-
synuclein neuronal accumulation. 
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Figure 32. LRRK2 regulates α-synuclein protein expression post-transcriptionally 
and this regulation is dependent on the length of SNCA mRNA transcript’s 3’ 
UTR. (A) α-Synuclein mRNA transcript can either undergo protein translation or 
inhibition of translation via microRNA/RISC complex pathway. (B) LRRK2 
negatively mediated miR-mediated translational repression. (C) LRRK2’s effects 
on translation are inhibited when its kinase activity is inhibited.  
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Future Studies 
 
We found that LRRK2 can regulate α-synuclein protein expression post-
transcriptionally via a miR pathway and this regulation is dependent on LRRK2 
kinase function. As these data implicate a novel mechanism through which 
LRRK2 can regulate α-synuclein biology and provide insights in potential drug 
targets, it will be interesting to investigate and to understand how LRRK2 kinase 
function contributes to this regulation. An interesting question to address is to 
investigate which protein(s) in the miR pathway does the kinase domain of 
LRRK2 phosphorylate, leading to an inhibition of the miR-mediated translational 
repression through the RISC complex. In addition, it will be interesting to look at 
the SNCA mRNA transcript levels for both short and long 3’ UTR transcript 
isoform in various conditions with and without wild-type LRRK2 and its disease-
linked variants and compare if there is a difference in their levels. The results 
may tell us if there is a difference in transcript stability between the two isoforms, 
which may in turn lead to different amounts of α-synuclein protein being 
translated. 
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